CA2555209A1 - Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions - Google Patents
Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions Download PDFInfo
- Publication number
- CA2555209A1 CA2555209A1 CA002555209A CA2555209A CA2555209A1 CA 2555209 A1 CA2555209 A1 CA 2555209A1 CA 002555209 A CA002555209 A CA 002555209A CA 2555209 A CA2555209 A CA 2555209A CA 2555209 A1 CA2555209 A1 CA 2555209A1
- Authority
- CA
- Canada
- Prior art keywords
- peptidoglycan
- peritoneal dialysis
- glucose polymer
- reagent
- icodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000385 dialysis solution Substances 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 238000001514 detection method Methods 0.000 title abstract description 33
- 239000012569 microbial contaminant Substances 0.000 title abstract description 5
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims abstract description 107
- 108010013639 Peptidoglycan Proteins 0.000 claims abstract description 107
- 229920002177 Icodextrin Polymers 0.000 claims abstract description 92
- 229940016836 icodextrin Drugs 0.000 claims abstract description 89
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 56
- 239000008103 glucose Substances 0.000 claims abstract description 47
- 229920000642 polymer Polymers 0.000 claims abstract description 44
- 206010034674 peritonitis Diseases 0.000 claims abstract description 22
- 238000000502 dialysis Methods 0.000 claims description 68
- 239000000243 solution Substances 0.000 claims description 37
- 239000003153 chemical reaction reagent Substances 0.000 claims description 35
- 108090001005 Interleukin-6 Proteins 0.000 claims description 18
- 230000004044 response Effects 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 108010069727 pro-phenoloxidase Proteins 0.000 claims description 11
- 241000255789 Bombyx mori Species 0.000 claims description 9
- 102000012479 Serine Proteases Human genes 0.000 claims description 9
- 108010022999 Serine Proteases Proteins 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 5
- 238000010998 test method Methods 0.000 claims description 2
- 206010071648 Noninfectious peritonitis Diseases 0.000 abstract description 38
- 238000012360 testing method Methods 0.000 abstract description 26
- 230000001580 bacterial effect Effects 0.000 abstract description 11
- 238000011109 contamination Methods 0.000 abstract description 10
- 210000002421 cell wall Anatomy 0.000 abstract description 9
- 230000000813 microbial effect Effects 0.000 abstract description 6
- 241000192125 Firmicutes Species 0.000 abstract description 5
- 239000003550 marker Substances 0.000 abstract description 4
- 239000002158 endotoxin Substances 0.000 description 29
- 239000000047 product Substances 0.000 description 19
- 102000004889 Interleukin-6 Human genes 0.000 description 17
- 239000002510 pyrogen Substances 0.000 description 17
- 239000000126 substance Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000011046 pyrogen test Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 230000001698 pyrogenic effect Effects 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 210000003567 ascitic fluid Anatomy 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 210000003200 peritoneal cavity Anatomy 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000356 contaminant Substances 0.000 description 6
- 238000001631 haemodialysis Methods 0.000 description 6
- 230000000322 hemodialysis Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 238000002794 lymphocyte assay Methods 0.000 description 6
- 231100000706 no observed effect level Toxicity 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010070419 Chemical peritonitis Diseases 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000008121 dextrose Substances 0.000 description 5
- 238000012454 limulus amebocyte lysate test Methods 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004303 peritoneum Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 241001147780 Alicyclobacillus Species 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940049774 extraneal Drugs 0.000 description 3
- 239000002880 extraneal Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000195628 Chlorophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000011213 bioburden testing Methods 0.000 description 2
- 238000009640 blood culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108010052620 leukocyte endogenous mediator Proteins 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012956 testing procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001063273 Alicyclobacillus acidiphilus Species 0.000 description 1
- 241000640374 Alicyclobacillus acidocaldarius Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101000988741 Bombyx mori CLIP domain-containing serine protease HP8 Proteins 0.000 description 1
- 101100030424 Bombyx mori PPAE gene Proteins 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000667653 Duta Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 238000011050 LAL assay Methods 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- IWIANZLCJVYEFX-RYUDHWBXSA-N Pro-Phe Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 IWIANZLCJVYEFX-RYUDHWBXSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010069568 Ultrafiltration failure Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- -1 corn starch Natural products 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 150000004676 glycans Chemical group 0.000 description 1
- 210000005256 gram-negative cell Anatomy 0.000 description 1
- 210000005255 gram-positive cell Anatomy 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4722—Proteoglycans, e.g. aggreccan
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- External Artificial Organs (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions are provided. A novel cause of aseptic peritonitis is provided--aseptic peritonitis associated with gram positive microbial contamination of a dialysis solution. Peptidoglycan is a major component of a gram positive bacterial cell wall and thus can serve as a marker for gram positive bacteria. In this regard, testing for peptidoglycans can be utilized to effectively prevent peritonitis in patients that use the peritoneal dialysis solutions, such as peritoneal dialysis solutions that contain a glucose polymer including an icodextrin and the like.
Description
SPECIFICATION
TITLE OF THE INVENTION
"METHODS AND COMPOSITIONS FOR DETECTION OF MICROBIAL
CONTAMINANTS IN PERITONEAL DIALYSIS SOLUTIONS"
BACKGROUND OF THE TNVENTION
The present invention generally relates to the detection of gram positive microbial contaminants. More specifically, the present invention relates to methods and compositions that employ the detection of peptidoglycan in peritoneal dialysis solutions. Peptidoglycans are major cell wall components of gram positive organisms and thus serve as a good marker of these microbes.
Due to disease or insult or other causes, the renal system can fail. Tn renal failure of any cause, there are several physiological derangements. The balance of water, minerals (e.g., Na, K, Cl, Ca, P, Mg, SO4) and the excretion of a daily metabolic load of fixed ions is no longer possible in renal failure. During renal failure, toxic end products of nitrogen metabolism (e.g., urea, creatinine, uric acid, and the Like) can accumulate in blood and tissues.
Dialysis processes have been devised for the separation of elements in a solution by diffusion across a semi-permeable membrane (diffusive solute transport) across a concentration gradient. Examples of dialysis processes include hemodialysis, peritoneal dialysis and hemofiltration.
Hemodialysis treatment utilizes the patient's blood to remove waste, toxins, and excess water from the patient. The patient is connected to a hemodialysis machine and the patient's blood is pumped through the machine. Catheters or the Iike are inserted into the patient's veins and arteries to connect the blood flow to and from the hemodialysis machine. Waste, toxins, and excess water are removed from the patient's blood and the blood is infused back into the patient. Hemodialysis treatments can last several hours and are generally performed in a treatment center about three or four times per week.
To overcome the disadvantages often associated with classical hemodialysis, other techniques were developed, such as peritoneal dialysis.
Peritoneal dialysis utilizes the patient's own peritoneum as a semipermeable membrane. The peritoneum is the membranous lining of the body cavity that, due to the large number of blood vessels and capillaries, is capable of acting as a natural semipermeable membrane.
In peritoneal dialysis, a sterile dialysis solution is introduced into the peritoneal cavity utilizing a catheter or the like. After a sufficient period of time, an exchange of solutes between the dialysate and the blood is achieved. Fluid removal is achieved by providing a suitable osmotic gradient from the blood to the dialysate to permit water outflow from the blood. This allows a proper acid-base, electrolyte and fluid balance to be returned to the blood. The dialysis solution is simply drained from the body cavity through the catheter. Examples of different types of peritoneal dialysis include continuous ambulatory peritoneal dialysis, automated peritoneal dialysis and continuous flow peritoneal dialysis.
Standard peritoneal dialysis solutions contain dextrose to effect transport of water and metabolic waste products across the peritoneum. Although dextrose has the advantage of being relatively safe and inexpensive, it has a number of disadvantages.
Because of the small size, dextrose is rapidly transported through the peritoneum, thus leading to the loss of osmotic gradient and loss of ultrafiltration within about 2 to 4 hours of infusion. It has been suggested that the ultrafiltration characteristics of peritoneal dialysis solutions could be improved by replacing dextrose with large molecular weight substances, such as glucose polymers. An example of a novel high molecular weight agent is icodextrin. Dialysis solutions containing icodextrin are commercially available and have been found to be useful in treating patients with end stage renal disease.
Peritonitis is a major complication of peritoneal dialysis. Clinical suspicion of peritonitis is prompted by the development of a cloudy-appearing dialysate in combination with variable clinical manifestations that may include abdominal pain, nausea, vomiting, diarrhea and fever. See, for example, Vas SI: Peritonitis.
In: Nolph KD, ed. Peritoneal Dialysis. 3rd ed. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1989:261-84. Most episodes of peritonitis are caused by intraperitoneal bacterial infections, and the diagnosis is usually readily established by positive dialysate cultures. However, there are several well documented causes of non-infectious or sterile peritonitis. Aseptic or sterile peritonitis, which also is described as aseptic, chemical, or culture-negative peritonitis, is typically caused by a chemical or a foreign body irntant.
One of the major outbreaks of sterile peritonitis among patients on peritoneal dialysis occurred in 1977. This was attributed to intrinsic and occult endotoxin contamination of dialysis solution. Suspected provocative batches of peritoneal dialysate had endotoxin levels in the range of 2 to 2.5 endotoxin units (ELT)/mL. See, for example, Karanicolas S, Oreopoulos DG, Izatt SH, et al: Epidemic of aseptic peritonitis caused by endotoxin during chronic peritoneal dialysis, N Eragl J
Med 1977;296:1336-7. A similar epidemic of aseptic peritonitis caused by endotoxin contamination in continuous cycling peritoneal dialysis patients was reported in 1998.
See, for example, Mangram AJ, Archbald LK, Hupert M, et al: Outbreak of sterile peritonitis among continuous cycling peritoneal dialysis patients, Kidney Int 1988;54:1367-71. Other reported causes of aseptic peritonitis include intraperitoneal adminstered vancomycin (See, for example, Smith T, Baile G, Eisele G: Chemical peritonitis associated with intraperitoneal vancomycin, Anrz Pharnz 1991;25:602-3, and Chancy DI, Gouse SF: Chemical peritonitis secondary to intraperitoneal vancomycin, Am J Kidney Dis 1991;17:76-9), amphotericin B (See, for example, Benevent D, El Akoun N, Lagarde C: Dangers of administration of intraperitoneal amphotericin B in continuous ambulatory peritoneal dialysis, Press Med 1984;13:1844), and acetaldehyde (See, for example, Tuncer M, Sarikaya M, Sezer T, et al: Chemical peritonitis associated with high dialysate acetaldehyde concentrations, Nephrol Dial Transplant 2000;15:2037-40). A unique form of aseptic peritonitis, eosinophilic peritonitis, is a much more common entity that can occur shortly after the start of peritoneal dialysis. See, for example, Gokal R, Ramos JM, Ward MK, et al:
'Eosinophilic peritonitis' in CAPD, Clira Nephrol 1981;15:328-330.
As previously discussed, glucose polymers, such as icodextrin, can be used in place of dextrose in peritoneal dialysis solutions. Icodextrin is a polymer of glucose derived from the hydrolysis of corn starch. It has a molecular weight of 12-20,000 Daltons. Peritoneal dialysis solutions containing icodextrin as the osmotic agent are, in general, used for long dwell (>4hour) exchanges. The majority of glucose molecules in icodextrin are linearly linked with a (1-4) glucosidic bonds (>90%) while a small fraction (<10%) is linked by a (1-6) bonds.
TITLE OF THE INVENTION
"METHODS AND COMPOSITIONS FOR DETECTION OF MICROBIAL
CONTAMINANTS IN PERITONEAL DIALYSIS SOLUTIONS"
BACKGROUND OF THE TNVENTION
The present invention generally relates to the detection of gram positive microbial contaminants. More specifically, the present invention relates to methods and compositions that employ the detection of peptidoglycan in peritoneal dialysis solutions. Peptidoglycans are major cell wall components of gram positive organisms and thus serve as a good marker of these microbes.
Due to disease or insult or other causes, the renal system can fail. Tn renal failure of any cause, there are several physiological derangements. The balance of water, minerals (e.g., Na, K, Cl, Ca, P, Mg, SO4) and the excretion of a daily metabolic load of fixed ions is no longer possible in renal failure. During renal failure, toxic end products of nitrogen metabolism (e.g., urea, creatinine, uric acid, and the Like) can accumulate in blood and tissues.
Dialysis processes have been devised for the separation of elements in a solution by diffusion across a semi-permeable membrane (diffusive solute transport) across a concentration gradient. Examples of dialysis processes include hemodialysis, peritoneal dialysis and hemofiltration.
Hemodialysis treatment utilizes the patient's blood to remove waste, toxins, and excess water from the patient. The patient is connected to a hemodialysis machine and the patient's blood is pumped through the machine. Catheters or the Iike are inserted into the patient's veins and arteries to connect the blood flow to and from the hemodialysis machine. Waste, toxins, and excess water are removed from the patient's blood and the blood is infused back into the patient. Hemodialysis treatments can last several hours and are generally performed in a treatment center about three or four times per week.
To overcome the disadvantages often associated with classical hemodialysis, other techniques were developed, such as peritoneal dialysis.
Peritoneal dialysis utilizes the patient's own peritoneum as a semipermeable membrane. The peritoneum is the membranous lining of the body cavity that, due to the large number of blood vessels and capillaries, is capable of acting as a natural semipermeable membrane.
In peritoneal dialysis, a sterile dialysis solution is introduced into the peritoneal cavity utilizing a catheter or the like. After a sufficient period of time, an exchange of solutes between the dialysate and the blood is achieved. Fluid removal is achieved by providing a suitable osmotic gradient from the blood to the dialysate to permit water outflow from the blood. This allows a proper acid-base, electrolyte and fluid balance to be returned to the blood. The dialysis solution is simply drained from the body cavity through the catheter. Examples of different types of peritoneal dialysis include continuous ambulatory peritoneal dialysis, automated peritoneal dialysis and continuous flow peritoneal dialysis.
Standard peritoneal dialysis solutions contain dextrose to effect transport of water and metabolic waste products across the peritoneum. Although dextrose has the advantage of being relatively safe and inexpensive, it has a number of disadvantages.
Because of the small size, dextrose is rapidly transported through the peritoneum, thus leading to the loss of osmotic gradient and loss of ultrafiltration within about 2 to 4 hours of infusion. It has been suggested that the ultrafiltration characteristics of peritoneal dialysis solutions could be improved by replacing dextrose with large molecular weight substances, such as glucose polymers. An example of a novel high molecular weight agent is icodextrin. Dialysis solutions containing icodextrin are commercially available and have been found to be useful in treating patients with end stage renal disease.
Peritonitis is a major complication of peritoneal dialysis. Clinical suspicion of peritonitis is prompted by the development of a cloudy-appearing dialysate in combination with variable clinical manifestations that may include abdominal pain, nausea, vomiting, diarrhea and fever. See, for example, Vas SI: Peritonitis.
In: Nolph KD, ed. Peritoneal Dialysis. 3rd ed. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1989:261-84. Most episodes of peritonitis are caused by intraperitoneal bacterial infections, and the diagnosis is usually readily established by positive dialysate cultures. However, there are several well documented causes of non-infectious or sterile peritonitis. Aseptic or sterile peritonitis, which also is described as aseptic, chemical, or culture-negative peritonitis, is typically caused by a chemical or a foreign body irntant.
One of the major outbreaks of sterile peritonitis among patients on peritoneal dialysis occurred in 1977. This was attributed to intrinsic and occult endotoxin contamination of dialysis solution. Suspected provocative batches of peritoneal dialysate had endotoxin levels in the range of 2 to 2.5 endotoxin units (ELT)/mL. See, for example, Karanicolas S, Oreopoulos DG, Izatt SH, et al: Epidemic of aseptic peritonitis caused by endotoxin during chronic peritoneal dialysis, N Eragl J
Med 1977;296:1336-7. A similar epidemic of aseptic peritonitis caused by endotoxin contamination in continuous cycling peritoneal dialysis patients was reported in 1998.
See, for example, Mangram AJ, Archbald LK, Hupert M, et al: Outbreak of sterile peritonitis among continuous cycling peritoneal dialysis patients, Kidney Int 1988;54:1367-71. Other reported causes of aseptic peritonitis include intraperitoneal adminstered vancomycin (See, for example, Smith T, Baile G, Eisele G: Chemical peritonitis associated with intraperitoneal vancomycin, Anrz Pharnz 1991;25:602-3, and Chancy DI, Gouse SF: Chemical peritonitis secondary to intraperitoneal vancomycin, Am J Kidney Dis 1991;17:76-9), amphotericin B (See, for example, Benevent D, El Akoun N, Lagarde C: Dangers of administration of intraperitoneal amphotericin B in continuous ambulatory peritoneal dialysis, Press Med 1984;13:1844), and acetaldehyde (See, for example, Tuncer M, Sarikaya M, Sezer T, et al: Chemical peritonitis associated with high dialysate acetaldehyde concentrations, Nephrol Dial Transplant 2000;15:2037-40). A unique form of aseptic peritonitis, eosinophilic peritonitis, is a much more common entity that can occur shortly after the start of peritoneal dialysis. See, for example, Gokal R, Ramos JM, Ward MK, et al:
'Eosinophilic peritonitis' in CAPD, Clira Nephrol 1981;15:328-330.
As previously discussed, glucose polymers, such as icodextrin, can be used in place of dextrose in peritoneal dialysis solutions. Icodextrin is a polymer of glucose derived from the hydrolysis of corn starch. It has a molecular weight of 12-20,000 Daltons. Peritoneal dialysis solutions containing icodextrin as the osmotic agent are, in general, used for long dwell (>4hour) exchanges. The majority of glucose molecules in icodextrin are linearly linked with a (1-4) glucosidic bonds (>90%) while a small fraction (<10%) is linked by a (1-6) bonds.
Icodextrin was introduced into clinical practice in the: United Kingdom in and in other European countries beginning in 1996. Tlie clinical advantages of icodextrin for long dwells, especially in patients with high end high average transport status and loss of ultrafiltration, is well-accepted and contributed to its global popularity. See, for example, Wilkie ME, Plant MJ, Edwards L, et al:
Icodextrin 7.5%
dialysate solution (glucose polymer) in patients with ultrafiltration failure:
extension of technique survival, Perit Dial Int 1997;17:84-7; Wolfson 3VI, Piraino B, Hamburger RJ, Morton AR, for the Icodextrin Study Group: A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis, Ana J
Kidney Dis 2002;40:1055-65; and Mujais S, Nolph I~, Gokal R, et al: Evaluation and management of ultrafiltration problems in peritoneal dialysis, Perit Diat Int 2000;20(Suppl 4):S5-521.
Since the introduction of icodextrin for use in peritoneal dialysis solutions, sporadic cases of aseptic peritonitis have been reported. See, for example, Pinerolo MC, Porn MT, D'Amico G: Recurrent sterile peritonitis at onset of treatment with icodextrin, Perit Dial Int 1999;19:491-2; Williams PF: Timely initiation of dialysis.
Am J Kidney Dis 34:594-595, 1999; Williams PF, Foggensteiner L:
Sterile/allergic peritonitis with icodextrin in CAPD patients, Perit .Dial Int 2002;22:89-90;
Foggensteiner L, Bayliss J, Moss H, et al: Timely initiation of dialysis -single-exchange experiences in 39 patients starting peritoneal dialysis, Perit Dial Int 2002;22:471-6; Heering P, Brause M, Plum J, et al: Peritoneal reaction to icodextrin in a female patient on CAPD. Perit Dial Int 2001;21:321-2; D e1 Rosso G, Di Liberato L, Pirilli A, et al: A new form of acute adverse reaction to icodextrin in peritoneal dialysis patient, Nephrol Dial Transplafat 2000;15:927-S; Goffin E, Scheiff JM:
Transient sterile chemical peritonitis in a CAPD patient using icodextrin, Perit Dial Int 2002;22:90-1; Tintillier M, Pochet JM, Christophe JL, Scheiff JM, et al:
Transient sterile chemical peritonitis with icodextrin: clinical presentation, prevalence, and literature review, Perit Dial Int 2002;22:534-7; and Gokal R: Icodextrin-associated sterile peritonitis, Perit Dial Int 2002;22:445-8. These patients typically presented with cloudy dialysate, no abdominal pain, and dialysate cell counts varying from 300 to 3500/mm3, with variable percentages of neutrophils, lymphocytes, and macrophages. In general, there is no change in ultrafiltration profile or peritoneal permeability for solutes. Cultures were invariably negative with no evidence of peritoneal or peripheral blood eosinophilia. Moreover, all solution components and endotoxin levels fell within the product specifications, and the icodextrin-based peritoneal dialysis solutions met all current Pharmacopoeia standards.
Prompted by these reports, in 2001, the manufacturer of the icodextrin-containing solution (BAXTER HEALTHCARE CORPORATION) modified the Summary of Product Characteristics (SPC) to include cloudy effluent as an "undesirable side effect" of icodextrin.
Parenteral pharmaceutical products are required to be free of contaminating substances, such as substances that can cause fever. Because endotoxins derived from gram-negative bacteria are the most common contaminant in parenteral products, the historic pyrogens of concern are LPS. Current Pharmacopeia standards are that one of two tests for pyrogenic contamination is applied to parenteral products. These tests are the rabbit pyrogen test and the LAL assay. Although generally reliable, both tests have shortcomings. The rabbit test relies on a febrile response that in turn depends upon the elaboration of pyrogenic cytokines. The rabbit pyrogen testing may be falsely negative, if the pyrogen is at a concentration too low to induce a systemic response, but of sufficient magnitude to produce a local inflammatory reaction. In turn, the more sensitive LAL test does not detect pyrogens other than LPS. Pyrogens, like viruses, fungi, DNA, gram-positive exotoxins, or bacterial cell wall components from gram positive bacteria, such as peptidoglycan and the like, will not be detected by the LAL
test. See, for example, Dinarello CA, O'Conner JV, LoPreste G: Human leukocyte pyrogen test fox detection of pyrogenic material in growth hormone produced by recombinant Escherichia coli, J Clin Microbiol 1984;20:323-9; Poole S, Thorpe R, Meager A, et al: Detection of pyrogen by cytokine release, Lancet 1988;1(8577):130;
Ray A, Redhead K, Selkirk S, et al: Variability in LPS composition, antigenicity and reactogenicity of phase variants of Bordetella pertussis, FEM.S Microbiol Lett 1991;63:211-7; Taktak YS, Selkirk S, Bristow AF, et al: Assay of pyrogens by interleukin-6 release from monocytic cell lines, J Plaarm Pharmacol 1991;43:578-82;
and Fennrich S, Fischer M, Hartung T, et al: Detection of endotoxins and other pyrogens using human whole blood, Dev Biol Stand 1999;101:131-9.
The global outbreak of aseptic peritonitis observed with icodextrin-based peritoneal dialysis solutions as discussed above serves as a sentinel example of how contemporary parenteral products with microbial, non-endotoxin contaminants may be considered safe under Pharmacopoeia standards but provoke adverse clinical effects.
Therefore, a need exists to provide improved standards for parenteral products that employ detection procedures to better ensure that the paxentaral products are effectively free of contaminating substances.
SUMMARY OF THE INVENTION
The present invention generally relates to the detection of gram positive microbial contaminants. In particular, the present invention relates to methods and compositions that employ the detection of peptidoglycan in peritoneal dialysis solutions. The inventors have surprisingly discovered a novel cause of aseptic peritonitis--aseptic peritonitis associated with gram positive microbial contamination of a dialysis solution. Peptidoglycan is a major component of a gram positive bacterial cell wall and thus can serve as a marker for gram positive bacteria. Thus, testing for peptidoglycans can be utilized to effectively prevent peritonitis in pa_rtients that use the peritoneal dialysis solutions, such as peritoneal dialysis solutior~s that contain a glucose polymer including an icodextrin and the like.
Icodextrin is derived from corn starch, a natural product. It is yell known that products of natural origin are contaminated With a wide variety of micro-organisms.
The inventors have found that some natural products, such as corn starch, contain an acidophilic thermophilic bacteria, such as Alicyclobacillus acidocaldariuos.
The later organism is ubiquitous in the food industxy, particularly in acidic beverages.
It is the alicyclobacillus that produces guaiacol, which is a causative substance for an 'ofd flavour orange juice. See, for example, Matsubara H, Goto K, Ma_tsumara T, et al.
Alicyclobacillus acidiphilus sp. Nov., a novel thermo-acidophilic~ omega-alicyclic fatty acid-containing bacterium isolated from acidic beverages. Int J Syst Evol Microbio12002; 52:161-5.
Peritoneal dialysis solutions and parenteral solutions in general have not been recognized to have contaminated by this organism or its degradation products.
This is mainly because the current testing procedure for microbial contamination of peritoneal iialysis solutions and parenteral solutions in general are not capable of detecting this organism or its degradation products.
To this end, in an embodiment, the present invention provides a method for manufacturing a peritoneal dialysis solution. The method includes providing a glucose polymer-based solution; adding a reagent to the glucose polymer-bas ed solution wherein the reagent is capable of reacting with a peptidoglycan; determining an amount of the peptidoglycan using the reagent; and using the glucose polymer-based solution to provide the peritoneal dialysis solution if it is determined that a sufficiently low level of the peptidoglycan is present.
In an embodiment, the reaction initiates a serine protease cascade.
In an embodiment, the serine protease cascade includes a prophe<nol oxidase cascade.
In an embodiment, the reagent is derived from a silkworm larvae plasma.
In an embodiment, the amount of peptidoglycan is further determined by a colorimetric measurement in response to the reaction between the peptidoglycan and the reagent.
In an embodiment, the sufficiently low level of the peptidoglycan is about 10 ng/mL or less.
In an embodiment, the glucose polymer-based solution includes an icodextrin.
In an embodiment, the reagent is added to the icodextrin in a raw n:~aterial form that is used to make the glucose polymer-based solution.
In another embodiment, the present invention provides a method of providing peritoneal dialysis to a patient. The method includes preparing a peritoneal dialysis solution utilizing a reagent to ensure that the peritoneal dialysis solution has a sufficiently low level of a peptidoglycan so as to prevent peritonitis in the patient; and providing the peritoneal dialysis solution to the patient.
In an embodiment, the peritoneal dialysis solution includes an icoc»extrin-based solution.
In an embodiment, the peritoneal dialysis includes an automated peritoneal dialysis, a continuous ambulatory peritoneal dialysis and the like.
In an embodiment, the patient is monitored for peritonitis during peritoneal dialysis. For example, a dialysis effluent can be collected from the patient to determine an IL-6 response that correlates to an incidence of peritonitis.
In an embodiment, the reagent is used to determine if the amount of the peptidoglycan exceeds about 10 ng/mL in the peritoneal dialysis solution prior to use during peritoneal dialysis.
In yet another embodiment, the present invention provides a method of testing a peritoneal dialysis solution for an amount of a peptidoglycan that exceeds a level sufficient to cause peritonitis. The method includes adding a reagent to the peritoneal dialysis solution wherein the reagent is capable of reacting with the peptidoglycan to initiate a serine protease cascade; and determining the amount of the peptidoglycan.
For example, the icodextrin-based solution can be tested to determine if the amount of peptidoglycan exceeds about 10 ng/mL.
In still yet another embodiment, the present invention provides an icodextrin composition that includes a reagent capable of reacting with a peptidoglycan.
.
In an embodiment, a level of peptidoglycan can be established above which the product would produce sterile peritonitis.
In an embodiment, use of affinity columns with resins that bind peptidoglycan can be used to minimize the contamination of peptidoglycan in glucose polymers.
An advantage of the present invention is to provide improved peritoneal dialysis solutions.
Another advantage of the present invention is to provide improved methods for manufacturing and using peritoneal dialysis solutions that employ a detection protocol to determine the presence of peptidoglycan in the peritoneal dialysis solution.
Yet another advantage of the present invention is to provide improved testing procedures that can be employed to prevent peritonitis in patients that receive peritoneal dialysis therapy.
Yet still another advantage of the present invention is to provide an improved icodextrin composition that utilizes a detection procedure in the manufacture thereof to determine the presence of peptidoglycan.
Additional features and advantages of the present invention are described in, and will be apparent from, the following Detailed Description of the Invention and the figures.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 illustrates a correlation between IL-6 response in a PBMC assay and peptidoglycan concentration in icodextrin. IL-6 response was measured in freshly isolated monocytes from healthy volunteers. Each symbol and line represent duta from a single donor.
Figure 2 illustrates an effect of peptidoglycan on the infiltration of neutrophils in the peritoneal fluid of rats. Peritoneal fluid was collected six hours after single injection (35 mL/kg) of icodextrin containing peptidoglycan.
Figure 3 illustrates an effect of peptidoglycan on TNF-a in the peritoneal fluid of rats.
Figure 4 illustrates an effect of peptidoglycan on IL-6 in the peritoneal fluid of rats.
Figure 5 illustrates frequency (%) of aseptic peritonitis reported with use of icodextrin.
DETAILED DESCRIPTION OF THE INVENTION
The present invention generally relates to the detection of gram positive organisms and fragments thereof. In particular, the present invention relates to methods and compositions that employ the detection of peptidoglycarl in peritoneal dialysis solutions. The inventors have surprisingly discovered a novel cause of aseptic peritonitis--aseptic peritonitis associated with gram positive microbial contamination of a dialysis solution. Peptidoglycan is a major component of a gram positive bacterial cell wall and thus can serve as a marker for gram positive bacteria. Ln this regard, testing for peptidoglycans can be utilized to effectively prevent peritonitis in patients that use the peritoneal dialysis solutions, such as peritoneal dialysis solutions that contain a glucose polymer including an icodextrin and the like.
Aseptic peritonitis associated with icodextrin-based peritoneal dialysis solutions is believed to be the largest adverse event reported for a peritoneal dialysis solution due to a contaminant of microbial origin. Based on the experimental investigations as described in detail below, this suggests that peptidoglycan in the icodextrin-based peritoneal dialysis solution was the causative agent of aseptic peritonitis. Further, pharmacovigilence data as detailed below supports the effectiveness of the corrective action and manufacturing screening procedure to prevent the occurrence of peritonitis. These findings illustrate that while endotoxin is deservedly one of the more worrisome bacterial product that can cause adverse effects to patients, it is not the sole one. In this regard, non-endotoxin pyrogens, such as peptidoglycans, that have not been previously identified, are capable of producing clinically significant inflammation. Thus, this demonstrates that parenteral pharmaceutical products that pass the compendia) tests and so meet Pharmacopoeia standards may still require a further level of testing to effectively determine the efficacy and safe use of such products to better ensure quality of life issues associated with use of same.
In the present invention, non-LPS pyrogen contamination was recognized as a problem because peritoneal dialysis exchanges permitted the direct observation of peptidoglycan-induced inflammation in situ. Peptidoglycan is a heteropolyrner formed from (3 (1-4) linked N-acetylmuramic acid and N-acetyl-D-glucosamine residues crosslinked by peptide bridges. See, for example, Royce CL, Pardy RL:
Endotoxin-like properties of an extract from a symbiotic, eukaryotic cholerella-like green algae, J
Endotoxira Res 1996;3:437-44. The glycan backbone is chemically homogenous, whereas the peptides cross-linking the sugars vary. Peptidoglycan occupies approximately 40% by weight of gram positive cell wall, but about 1-10% of the total weight of the gram negative cell walls. Royce CL, Pardy RL: Endotoxin-like properties of an extract from a symbiotic, eukaryotic cholerella-like green algae, J
Endotoxin Res 1996;3:437-44. Peptidoglycan and another cell wall constituent, lipoteichoic acid, include virtually all of the major inflammatory inducing components of gram-positive cellular walls. See, for example, Sriskandan S, Cohen J: Gram-positive sepsis, In: Opal SM, Cross AS, eds. Bacterial Sepsis and Septic Shock, Philadelphia: W. B. Saunders Company, 1999:397-412.
Like endotoxins, peptidoglycans can induce cytokine production in a wide variety of cells and have long been recognized to have immunomodulatory actions.
See, for example, Garner RE, Hudson JA: Intravenous injection of candida-derived mannan results in elevated tumor necrosis factor alpha levels in serum, Infect Inzmun 1996;64:4561-6; and Schwab J: Phlogistic properties of peptidoglycan-polysaccharide polymers from cell walls of pathogenic and normal flora bacteria which colonize humans, Infect Imznun 1993;61:4535-9. However, peptidoglycans are several orders of magnitude less potent than endotoxins as provocateurs of these biological effects. See, for example, Henderson B, Poole S, Wilson M: Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis, Microbiol Rev 1996;60:316-41; and Nakagawa Y, Maeda H, Murai T: Evaluation of the in vitro pyrogen test system based on proinflammatory cytokine release from human monocytes: Comparison with a human whole blood culture test system and with the rabbit pyrogen test, Clirz Diag Lab Imznuzzol 2002;9:588-97. For example, the minimum pyrogenic dose of peptidoglycans in rabbits is 7.3 ~,g/kg, while that of endotoxins is 0.0027 ~,g/kg. See, for example, Henderson B, Poole S, Wilson M:
Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis, Microbiol Rev 1996;60:316-41.
In addition to the absence of pyrogenic containing substances, safety of parenteral products are generally defined by Pharmacopoeia tests to determine their sterility. Bacterial cultures are generally performed at neutral pH using an incubation temperature between 20-35°C. These are suboptimal conditions for the growth of thermophilic, acidophilic microorganisms such as Alic~clobacillus acidocaldarius that require an acid medium and elevated temperature for growth. Therefore, routinely employed "sterility definitions" and the supporting assays may fail to detect microorganisms that do not grow under conventional conditions. In an embodiment of the present application, acid hydrolysis at an elevated temperature is used for hydrolysis of starch to produce icodextrin. These manufacturing conditions are suitable for the growth of Alicycclobacillus acidocadarius, but discordant with those used to determine sterility based on bioburden.
As referenced above, a detailed description of the investigative findings are provided below in accordance with an embodiment of the present invention by way of example and without limitation:
CHEMICAL AND PHYSICAL INVESTIGATIONS
The majority of glucose molecules in icodextrin are linearly linked with a (1-4) glucosidic bonds (>90%), while a small fraction (<10%) are linked by a (1-6) bonds.
Molecular weight distribution of icodextrin was performed by gel permeation chromatography. The distribution of a(1-3 6 ) and a(l~ 4) glucosidic links in icodextrin was assessed by nuclear magnetic resonance spectroscopy. Volatile and semi-volatile organic impurities were examined by high performance liquid chromatography and mass spectroscopy.
DIALYSATE EFFLUENT ANALYSIS
Dialysate effluent samples from patients were analyzed for icodextrin metabolites, triglycerides, total protein and selective pyrogenic cytokines (IL-6, TL-1,Q
and TNF-a). Icodextrin metabolites were assayed using high performance anion exchange chromatography with pulsed amperometric detection. See, for example, Burke RA, Hvizd MG, Shockley TR: Direct determination of polyglucose metabolites in plasma using anion-exchange chromatography with pulsed amperometric detection, J Claromatogr B 1997;693:353-7. Triglyceride and protein analysis were performed with Boehringer Mannheim/Hitachi 911 Chemistry analyzer. Cytokine measurements were made using ELISA kits (R&D Systems, Minneapolis, MN).
MEASUREMENT OF PYROGENS
Endotoxin concentration in icodextrin solution was determined by a fixed point chromogenic LAL test. See, for example, Weary M, Dubczak J, Wiggins J, et al:
Validating an LAL chromogenic substrate pyrogen test for large volume parenterals, In: Watson SW, Levin J, Novitsky TJ, eds, Detection of bacterial endotoxin with limulus amebocyte lysate test. New York: Alan R. Liss, 1987:307-22. Rabbit pyrogen test was performed in accordance with the guidelines provided in the European Pharmacopeia. European Pharmacopoeia, Pyrogens, 4th ed. Strasbourg, France:
Council of Europe, 2002:131-2. An ex vivo pyrogen test that measures IL-6 response in freshly isolated peripheral blood mononuclear cells (PBMC) following exposure to a test substance was used to quantitate non-endotoxin pyrogens. See, for example, Dinarello CA, O'Conner JV, LoPreste G: Human leukocyte pyrogen test for detection of pyrogenic material in growth hormone produced by recombinant Escherichia coli, J
Clih Microbiol 1984;20:323-9; and Poole S, Thorpe R, Meager A, et al:
Detection of pyrogen by cytokine release, Lancet 1988;1 (8577):130.
MEASUREMENT OF PEPTIDOGLYCANS
Peptidoglycan (PG) quantitation was performed with the silkworm larvae plasma (SLP) test (Wako Pure Chemical Industries, Ltd., Osaka, Japan). See, for example, Tsuchiya M, Asahi N, Suzouki F: Detection of peptidoglycan and B-glucan with silkworm larvae plasma test, FEMS InznZUrzol Medical Micrbiol 1996;15:129-34;
and U.S. Patent No. 4,970,152. SLP contains all the factors of the prophenol oxidase (PPO) cascade, a self defense mechanism of insects. The PPO cascade is initiated by peptidoglycan, in which PPO is ultimately activated to phenol oxidase. The phenol oxidase activity is colorimetrically detected with 3,4-dihydroxyphenylalanine as a substrate. The limit of detection of peptidoglycan in icodextrin solution was found to be 7.4 nglmL. The SLP test does not detect endotoxins.
As fully disclosed in U.S. Patent No. 4,970,152, for example, the detection of peptidoglycan (or (3-G) can be carried out as follows. A sample containing the peptidoglycan is well mixed with a reagent that includes a fraction which specifically reacts with peptidoglycan ("PG") to prepare a reaction solution. After a certain period of time, an enzymatic activity, e.g., activity of BAEEase, PPAE, PO, etc., in the reaction solution can be measured by a conventional method and compared with calibration curves previously obtained by using PG standard solutions with known concentrations to determine the amount of PG.
Alternatively, it is possible to apply a phenomenon that a time required for the activation of PO depends on the concentration of PG in the sample. That is, after mixing the PG reagent with a sample in the presence of the substrate of PO, a time required for reaching a certain value of the amount of reaction product generated by PO is measured.
By way of example and not limitation, an experimental procedure that utilizes the SLP test can be conducted in accordance with an embodiment of the present invention as follows.
Peptidoglycan (PG) and (1,3)--D-glucan (BG) are components of the cell walls of gram positive bacteria and fungi, respectively. PG and BG are measured with the Silkworm Larvae Plasma (SLP) test. The SLP test contains all the factors of the pro-phenol oxidase (PPO) cascade, an important self defense mechanism of insects.
The PPO cascade is initiated by peptidoglycan, in which PPO converts 3,4-dihydroxyphenylalanine (DOPA) to melanin. The resulting formation of melanin is colorimetrically detected at 650 nm using a standard plate reader. The raw material icodextrin is tested undiluted and has a limit of detection (LOD) of 0.74 ng/ml (the lowest detectable standard point). The finished product, such as EXTRANEAL, is tested after diluting tenfold in order to mitigate the matrix inhibition caused by the presence of electrolytes. The sample dilution step results in a LOD of 7.4 ng/ml after correcting for the 1:10 dilution.
ANIMAL STUDIES
No Observed Effect Level (NOEL) for peptidoglycan in icodextrin was determined in a rat model. A total of 45 male Sprague-Dawley rats (Harlan Inc;
Indianapolis, IN, USA), weighing 255-280 g were divided into 9 equal groups.
Each group received a single intraperitoneal injection of icodextrin spiked with 0, l, 5, 10, 50, 100, 500, 1000 or 5000 ng/mL peptidoglycan at a dose of 35 mLlkg.
Peptidoglycan derived from Staphylococcus aureus (Toxin Technology Inc., Sarasota, FL, USA) was used in these experiments. Six hours post injection, the rats were sacrificed, and the fluid in the peritoneal cavity was quantitatively collected by determining the weight and volume. Peritoneal fluid was analyzed for nucleated cell counts and differential counts, total protein, 'and TL-6 and TNF-a concentrations.
STATISTICAL ANALYSIS
Post market surveillance data on several hundred batches of icodextrin manufactured between July 2000 and September 2002 were analyzed to determine an association between peptidoglycan level and the incidence of aseptic peritonitis. To accumulate sufficient complaint frequencies to effectively display complaints per million (CPM), data were classified into peptidoglycan level in a log scale, namely, ~.4, >7.4-15, >15-30, >30-60, and _60 ng/mL. For each of peptidoglycan concentration range, the total complaints and the total units sold were calculated. The CPM units sold were computed as the total complaints divided by the total units sold multiplied by one million. Negative binomial regression was used to assess the association between CPM and peptidoglycan level. The statistical analysis was performed using the SAS procedure GENMOD (SAS Institute, Cary, NC, USA).
CLINICAL CASES
According to reports received through the BAXTER HEALTHCARE
CORPORATION's global pharmacovigilance system in 2000, the frequency [(number of complaints = number of patients treated) x 100] of aseptic peritonitis was 0.095%.
There was a steady increase in reported cases in 2001 to a peak frequency of 1.04% in March 2002. The patients were rarely febrile or toxic in appearance; abdominal pain was modest to absent; the dialysate was cloudy and cellular with dialysate cell counts varying from 300 to 3500/mm3 (variable percentages of neutrophils, lymphocytes, and macrophages without eosinophils). Unlike bacterial peritonitis, there was no change in ultrafiltration or peritoneal permeability for small solutes. Blood and dialysate cultures were invariably negative. Antibiotics were variably instituted by the local physicians.
All clinical signs resolved upon stopping icodextrin. In some cases, icodextrin was restarted, and aseptic peritonitis recurred. BAXTER HEALTHCARE
CORPORATION initiated a voluntary worldwide recall of several hundred batches of icodextrin in May 2002.
Extensive chemical and physical investigations of recalled icodextrin batches were performed. These analyses did not reveal any differences in molecular weight distribution of icodextrin, percent branching of glucosidic bonds, or trace volatile and semi-volatile organic impurities between the batches associated with aseptic peritonitis and those not associated with adverse clinical events. All solution components of complaint batches of icodextrin-containing dialysate were within the product specifications and met current Pharmacopoeia standards.
DIALYSATE EFFLUENT ANALYSIS
A marked elevation in IL-6 concentration was observed in the dialysate effluent from a patient with aseptic peritonitis compared to control effluent (>5000 versus 59 pg/mL, respectively). An increase in protein concentration was noted with the complaint sample compared to the control (236 mg/dL versus 125 mg/dL, respectively). There was no difference in icodextrin and its metabolites (glucose polymers with degree of polymerization from 2 to 7) between the complaint and control samples. These results indicated that neither icodextrin nor its metabolites were the likely cause of aseptic peritonitis.
PYROGEN ANALYSIS OF ICODEXTRIN
Endotoxin levels in all the icodextrin samples associated with aseptic peritonitis were found to be within the product limit (c 0.25 EU/mL) as determined by i the LAL test. In rabbit pyrogen tests, there was no increase in temperature with either complaint or non-complaint icodextrin batches. However, an increase in IL-6 response in the in vitro PBMC assay was observed with both complaint icodextrin-containing dialysate batches and the icodextrin raw material used to manufacture the complaint batches of peritoneal dialysate as illustrated in Table 1 below:
Tablel : IL-6 response of complaint and non-complaint batches of icodextrin in the PBMC assay. In this assay, an IL-6 response of greater than 500 pg/mL is considered a positive pyrogenic response.
Test Sample Donor 023 Donor 022 Donor 011 pg/mL pg/mL pg/mL
Control Mediums 45 24 50 Positive Control 12,000 10,000 10,000 Negative Control 130 92 150 Icodextrin (non-complaint)330 350 110 Icodextrin (complaint) 5,100 7,000 970 Icodextrin (complaint) 4,200 4,200 700 Icodextrin raw material 9,300 780 1,600 (complaint) Icodextrin raw material 91 100 130 (non-complaint) aEagle minimum essential medium with supplemental components, bBaxter experimental product, °Glucose containing standard peritoneal dialysis solution The IL-6 provoking substance in the complaint samples was unaffected in the presence of polymyxin B, thus suggesting that it was not LPS. See, for example, Pool EJ, Johaar G, James S, et al: Differentiation between endotoxin and non-endotoxin pyrogens in human albumin solutions using an ex vivo whole blood culture assay, J
Immunoassay 1999;20:79-89. In a filtration experiment using a 30 kD molecular weight cut-off filter, the contaminant producing the inflammatory response in the PBMC assay was found in the retentate, suggesting the molecular weight of the substance was >30 kD, i.e. larger than icodextrin. The negative assays for LPS, but positive PBMC IL-6 response indicated that the likely cause of aseptic peritonitis was a non-endotoxin, pyrogen contaminant in icodextrin raw material used to manufacture the final peritoneal dialysis solution.
PEPTIDOGLYCAN AND MICROBIOLOGICAL ANALYSIS
Analysis of several hundred recalled batches of icodextrin indicated that 41 of the batches were contaminated with peptidoglycan that was detected by the SLP
assay. Peptidoglycan concentrations ranged from the detection limit of 7.4 ng/mL to 303 ng/mL. Because the manufacture of icodextrin from maltodextrin requires heat and acidification, a microbiological investigation for the presence of fastidious organisms was undertaleen. Early steps of icodextrin were found to be contaminated with a thermophilic, acidiophilic, gram positive organism, Alicyclobacillus acidocaldarius. Alicyclobacillus was the source of the contaminating peptidoglycan.
Heat and sterile filtration procedures applied to the near final product eliminated the bacteria, but not the peptidogycan contaminants. A positive correlation was found between peptidoglycan levels in icodextrin and the IL-6 response observed in the PBMC assay (See, Fig.l). Substantial variability in the IL-6 response was seen between donors suggesting a range of sensitivities to peptidoglycan.
ANIMAL STUDIES
The effects of intraperitoneal administration of peptidoglycan in rats was investigated in order to establish a NOEL. This can be used to establish a regulatory specification for icodextrin manufacturing. Total protein, white blood cells and neutrophils were elevated in the peritoneal fluid of icodextrin +
peptidoglycan-treated rats compared to control rats that received icodextrin without peptidoglycan.
Infiltration of neutrophils in peritoneal fluid showed a dose dependent increase with a NOEL at 100 ng/mL (See, Fig.2). Both inflammatory cytokines showed dose dependent increases with NOEL values at 10 ng/mL for TNF-a (See, Fig.3) and ng/mL for IL-6 (See, Fig.4). The lowest NOEL for peptidoglycan was for TNF-a response which was 10 ng/mL.
CORRELATION BETWEEN PEPTIDOGLYCAN AND ASEPTIC PERITONITIS
A positive correlation was found between peptidoglycan concentration in icodextrin and CPM as illustrated in Table 2 below:
Table 2: Correlation between Complaints Per Million (CPM) units sold and peptidoglycan concentration in icodextrin solution Peptidoglycan (ng/mL)Total units Total complaintsCPM per units sold solda <'7.4 2906643 53 18.2 > 7.4 - 15 835539 10 12.0 > 15 - 30 349503 10 28.6 > 30 - 60 231330 8 ' 34.6 >_60 415099 105 253.0 aComplaints Per Million (CPM) units sold was computed as the total complaints divided by the total units sold multiplied by one million.
The baseline CPM was 18.2, when peptidoglycan levels were below the detection limit of 7.4 ng/mL. In contrast, the CPM was 252.9, when peptidoglycan levels were equal to or greater than 60 ng/mL. The association between CPM and peptidoglycan was highly significant (p<0.0001).
INCIDENCE OF ASEPTIC PERITONITIS FOLLOWING CORRECTIVE ACTION
In May 2002, BAXTER HEALTHCARE CORPORATION recalled all batches of icodextrin contaminated with peptidoglycan at a concentration >10 ng/mL, as well as all lots that were not assayed for peptidoglycan at the time of the recall.
In addition, an internal regulatory specification for peptidoglycan below the detection limit of the assay (<7.4 ng/mL) was implemented for product release. Routine, serial monitoring for peptidoglycan and thermophilic bacteria was implemented. The peptidoglycan concentrations in all the recent batches manufactured have been below the detection limit of the SLP test and are. devoid of an IL-6 eliciting agent by the PBMC
assay.
Fig. 5 shows the incidence rate of aseptic peritonitis by month beginning September 2001 to January 2003. The frequency of complaints has decreased from a peak value of 1.04% in March 2002 to 0.013% in January 2003 following the implementation of corrective actions. The number of patients using a commercially available peritoneal dialysis ' solution known as EXTRANEAL from BAXTER
HEALTHCARE CORPORATION during this period remained at approximately 7,000. These results suggest that corrective actions have been effective in preventing excess complaints of aseptic peritonitis due to peptidoglycan contamination in icodextrin-containing dialysis solution.
As previously discussed, the present invention relates to methods and compositions that employ the detection of peptidoglycan in peritoneal dialysis solutions. This allows testing for bacterial fragments as peptidoglycans are the major cell wall component of gram positive organisms. In this regard, peptidoglycan detection can be effectively utilized to prevent peritonitis in patients that use the peritoneal dialysis solutions, such as peritoneal dialysis solutions that contain a glucose polymer including icodextrin and the like.
It should be appreciated that compositions, peritoneal dialysis solutions and methods of manufacturing and using same can be provided in any suitable manner in accordance with an embodiment of the present invention. In an embodiment, the present invention provides bioburden testing, such as bioburden testing for acidophilic thermophilic organisms according to standard procedures as described in various Pharmacopoeias. This type of testing can be utilized as an added level of testing in addition to the testing for bacterial fragments by detection of peptidoglycans as previously discussed.
In an embodiment, the present invention provides methods for manufacturing a peritoneal dialysis solution. The method can include any suitable number and type of processing stages. For example, the process includes providing a glucose polymer;
adding a reagent to the glucose polymer wherein the reagent is capable of reacting with a peptidoglycan; determining an amount of the peptidoglycan; and using the glucose polymer to make the peritoneal dialysis solution if it is determined that a sufficiently low level of the peptidoglycan is present in the glucose polymer.
If the amount of peptidoglycan or the like exceeds this level, such as about 10 ng/mL
or less, the glucose polymer can be further processed to remove the peptidoglycan or the like in order to achieve a sufficiently low level of same. The glucose polymer can be further processed in any suitable manner. In an embodiment, the glucose polymer can be processed with any suitable number and type of separation devices, such as an affinity device and/or the like.
In an embodiment, the present invention provides compositions, such as glucose polymer compositions that can be used to prepare peritoneal dialysis solutions.
A variety of different and type of compositions and solutions containing same can be utilized. For example, the type of compositions and solutions can same can be found in U.S. Patent No. 4,761,237, entitled "PERITONEAL DIALYSIS SOLUTION
CONTAINING CARBOHYDRATE POLYMERS; LT.S. Patent No. 4,886,789, entitled "PERITONEAL DIALYSIS AND COMPOSITIONS FOR USE THEREIN"; U.S.
Patent No. 6,077,836, entitled "PERITONEAL DIALYSIS AND COMPOSITIONS
FOR USE THEREIN"; AND U.S. Patent No. 6,248,726 Bl, entitled "METHOD OF
PERITONEAL DIALYSIS USING GLUCOSE POLYMER SOLUTIONS, the disclosures of which in their entirety are incorporated herein by reference.
Additional examples of compositions and solutions containing same can be can be found in U.S.
Patent Application No.lO/327,264, entitled BIOCOMPATIBLE DIALYSIS FLUIDS
CONTAINING ICODEXTR1NS, filed on December 20, 2002; and U.S. Patent Application No. 09/206,063, entitled PERITONEAL DIALYSIS SOLUTION
CONTAINING MODIFIED ICODEXTRINS, filed on December 4, 1998, the disclosures of which in their entirety are incorporated herein by reference.
In an embodiment, the peritoneal dialysis solutions can include EXTRANEAL by BAXTER
HEALTHCARE CORPORATION or suitable modifications thereof.
In an embodiment, the present invention includes methods of providing peritoneal dialysis, such as continuous ambulatory peritoneal dialysis and automated peritoneal dialysis. In continuous ambulatory peritoneal dialysis, the patient performs several drain, fill, and dwell cycles during the day, for example, about four times per day. Each treatment cycle, which includes a drain, fill and dwell, takes about four hours.
Automated peritoneal dialysis is similar to continuous ambulatory peritoneal dialysis in that the dialysis treatment includes a drain, fill, and dwell cycle. However, a dialysis machine automatically performs three or more cycles of peritoneal dialysis treatment, typically overnight while the patient sleeps.
With automated peritoneal dialysis, an automated dialysis machine fluidly connects to an implanted catheter or the like. The automated dialysis machine also fluidly connects to a source or bag of fresh dialysis solution and to a fluid drain. The dialysis machine pumps spent dialysis solution from the peritoneal cavity, through the catheter, to the drain. The dialysis machine then pumps fresh dialysis solution from the source, through the catheter, and into the patient's peritoneal cavity.
The automated machine allows the dialysis solution to dwell within the cavity so that the transfer of waste, toxins and excess water from the patient's bloodstream to the dialysis solution can take place. A computer controls the automated dialysis machine so that the dialysis treatment occurs automatically when the patient is connected to the dialysis machine, for example, when the patient sleeps. In this regard, the dialysis system automatically and sequentially pumps fluid into the peritoneal cavity, allows for dwell, pumps fluid out of the peritoneal cavity, and repeats the procedure.
Several drain, fill, and dwell cycles will occur during the treatment. Also, a final volume "last fill" is typically used at the end of the automated dialysis treatment, which remains in the peritoneal cavity of the patient when the patient disconnects from the dialysis machine for the day. Automated peritoneal dialysis frees the patient from having to manually perform the drain, dwell, and fill steps during the day. In an embodiment, automated peritoneal dialysis can be performed by utilizing an admix device, such as ADMIX HOMECHOICE by BAXTER HEALTHCARE
CORPORATION or suitable modifications thereof.
In an embodiment, the present invention provides a test to determine if a peritoneal dialysis solution, such as an icodextrin-based solution, includes peptidoglycan that exceeds a level sufficient to cause peritonitis in the patient that uses same. The present invention provides a detection protocol that utilizes a reagent, such a reagent derived from a silkworm larvae plasma, for such purpose. It should be appreciated that the detection procedure can be carried out at any suitable stage prior to use of the peritoneal dialysis solution.
For example, the reagent can be added to a glucose polymer composition, such as an icodextrin composition, in raw material form to determine the presence of peptidoglycan. If the level of peptidoglycan is at a sufficiently low level, the composition can then be utilized to prepare the peritoneal dialysis solution.
In another embodiment, the reagent can be added to the peritoneal dialysis solution, such as after the sterilization process in finished product form. For example, the reagent can be added to the peritoneal dialysis solution that is contained within any suitable solution bag, such as a single-chambered solution bag or a mufti-chamber solution bag.
An example of a mufti-chamber solution bag or container is provided in U.S.
Patent No.
Icodextrin 7.5%
dialysate solution (glucose polymer) in patients with ultrafiltration failure:
extension of technique survival, Perit Dial Int 1997;17:84-7; Wolfson 3VI, Piraino B, Hamburger RJ, Morton AR, for the Icodextrin Study Group: A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis, Ana J
Kidney Dis 2002;40:1055-65; and Mujais S, Nolph I~, Gokal R, et al: Evaluation and management of ultrafiltration problems in peritoneal dialysis, Perit Diat Int 2000;20(Suppl 4):S5-521.
Since the introduction of icodextrin for use in peritoneal dialysis solutions, sporadic cases of aseptic peritonitis have been reported. See, for example, Pinerolo MC, Porn MT, D'Amico G: Recurrent sterile peritonitis at onset of treatment with icodextrin, Perit Dial Int 1999;19:491-2; Williams PF: Timely initiation of dialysis.
Am J Kidney Dis 34:594-595, 1999; Williams PF, Foggensteiner L:
Sterile/allergic peritonitis with icodextrin in CAPD patients, Perit .Dial Int 2002;22:89-90;
Foggensteiner L, Bayliss J, Moss H, et al: Timely initiation of dialysis -single-exchange experiences in 39 patients starting peritoneal dialysis, Perit Dial Int 2002;22:471-6; Heering P, Brause M, Plum J, et al: Peritoneal reaction to icodextrin in a female patient on CAPD. Perit Dial Int 2001;21:321-2; D e1 Rosso G, Di Liberato L, Pirilli A, et al: A new form of acute adverse reaction to icodextrin in peritoneal dialysis patient, Nephrol Dial Transplafat 2000;15:927-S; Goffin E, Scheiff JM:
Transient sterile chemical peritonitis in a CAPD patient using icodextrin, Perit Dial Int 2002;22:90-1; Tintillier M, Pochet JM, Christophe JL, Scheiff JM, et al:
Transient sterile chemical peritonitis with icodextrin: clinical presentation, prevalence, and literature review, Perit Dial Int 2002;22:534-7; and Gokal R: Icodextrin-associated sterile peritonitis, Perit Dial Int 2002;22:445-8. These patients typically presented with cloudy dialysate, no abdominal pain, and dialysate cell counts varying from 300 to 3500/mm3, with variable percentages of neutrophils, lymphocytes, and macrophages. In general, there is no change in ultrafiltration profile or peritoneal permeability for solutes. Cultures were invariably negative with no evidence of peritoneal or peripheral blood eosinophilia. Moreover, all solution components and endotoxin levels fell within the product specifications, and the icodextrin-based peritoneal dialysis solutions met all current Pharmacopoeia standards.
Prompted by these reports, in 2001, the manufacturer of the icodextrin-containing solution (BAXTER HEALTHCARE CORPORATION) modified the Summary of Product Characteristics (SPC) to include cloudy effluent as an "undesirable side effect" of icodextrin.
Parenteral pharmaceutical products are required to be free of contaminating substances, such as substances that can cause fever. Because endotoxins derived from gram-negative bacteria are the most common contaminant in parenteral products, the historic pyrogens of concern are LPS. Current Pharmacopeia standards are that one of two tests for pyrogenic contamination is applied to parenteral products. These tests are the rabbit pyrogen test and the LAL assay. Although generally reliable, both tests have shortcomings. The rabbit test relies on a febrile response that in turn depends upon the elaboration of pyrogenic cytokines. The rabbit pyrogen testing may be falsely negative, if the pyrogen is at a concentration too low to induce a systemic response, but of sufficient magnitude to produce a local inflammatory reaction. In turn, the more sensitive LAL test does not detect pyrogens other than LPS. Pyrogens, like viruses, fungi, DNA, gram-positive exotoxins, or bacterial cell wall components from gram positive bacteria, such as peptidoglycan and the like, will not be detected by the LAL
test. See, for example, Dinarello CA, O'Conner JV, LoPreste G: Human leukocyte pyrogen test fox detection of pyrogenic material in growth hormone produced by recombinant Escherichia coli, J Clin Microbiol 1984;20:323-9; Poole S, Thorpe R, Meager A, et al: Detection of pyrogen by cytokine release, Lancet 1988;1(8577):130;
Ray A, Redhead K, Selkirk S, et al: Variability in LPS composition, antigenicity and reactogenicity of phase variants of Bordetella pertussis, FEM.S Microbiol Lett 1991;63:211-7; Taktak YS, Selkirk S, Bristow AF, et al: Assay of pyrogens by interleukin-6 release from monocytic cell lines, J Plaarm Pharmacol 1991;43:578-82;
and Fennrich S, Fischer M, Hartung T, et al: Detection of endotoxins and other pyrogens using human whole blood, Dev Biol Stand 1999;101:131-9.
The global outbreak of aseptic peritonitis observed with icodextrin-based peritoneal dialysis solutions as discussed above serves as a sentinel example of how contemporary parenteral products with microbial, non-endotoxin contaminants may be considered safe under Pharmacopoeia standards but provoke adverse clinical effects.
Therefore, a need exists to provide improved standards for parenteral products that employ detection procedures to better ensure that the paxentaral products are effectively free of contaminating substances.
SUMMARY OF THE INVENTION
The present invention generally relates to the detection of gram positive microbial contaminants. In particular, the present invention relates to methods and compositions that employ the detection of peptidoglycan in peritoneal dialysis solutions. The inventors have surprisingly discovered a novel cause of aseptic peritonitis--aseptic peritonitis associated with gram positive microbial contamination of a dialysis solution. Peptidoglycan is a major component of a gram positive bacterial cell wall and thus can serve as a marker for gram positive bacteria. Thus, testing for peptidoglycans can be utilized to effectively prevent peritonitis in pa_rtients that use the peritoneal dialysis solutions, such as peritoneal dialysis solutior~s that contain a glucose polymer including an icodextrin and the like.
Icodextrin is derived from corn starch, a natural product. It is yell known that products of natural origin are contaminated With a wide variety of micro-organisms.
The inventors have found that some natural products, such as corn starch, contain an acidophilic thermophilic bacteria, such as Alicyclobacillus acidocaldariuos.
The later organism is ubiquitous in the food industxy, particularly in acidic beverages.
It is the alicyclobacillus that produces guaiacol, which is a causative substance for an 'ofd flavour orange juice. See, for example, Matsubara H, Goto K, Ma_tsumara T, et al.
Alicyclobacillus acidiphilus sp. Nov., a novel thermo-acidophilic~ omega-alicyclic fatty acid-containing bacterium isolated from acidic beverages. Int J Syst Evol Microbio12002; 52:161-5.
Peritoneal dialysis solutions and parenteral solutions in general have not been recognized to have contaminated by this organism or its degradation products.
This is mainly because the current testing procedure for microbial contamination of peritoneal iialysis solutions and parenteral solutions in general are not capable of detecting this organism or its degradation products.
To this end, in an embodiment, the present invention provides a method for manufacturing a peritoneal dialysis solution. The method includes providing a glucose polymer-based solution; adding a reagent to the glucose polymer-bas ed solution wherein the reagent is capable of reacting with a peptidoglycan; determining an amount of the peptidoglycan using the reagent; and using the glucose polymer-based solution to provide the peritoneal dialysis solution if it is determined that a sufficiently low level of the peptidoglycan is present.
In an embodiment, the reaction initiates a serine protease cascade.
In an embodiment, the serine protease cascade includes a prophe<nol oxidase cascade.
In an embodiment, the reagent is derived from a silkworm larvae plasma.
In an embodiment, the amount of peptidoglycan is further determined by a colorimetric measurement in response to the reaction between the peptidoglycan and the reagent.
In an embodiment, the sufficiently low level of the peptidoglycan is about 10 ng/mL or less.
In an embodiment, the glucose polymer-based solution includes an icodextrin.
In an embodiment, the reagent is added to the icodextrin in a raw n:~aterial form that is used to make the glucose polymer-based solution.
In another embodiment, the present invention provides a method of providing peritoneal dialysis to a patient. The method includes preparing a peritoneal dialysis solution utilizing a reagent to ensure that the peritoneal dialysis solution has a sufficiently low level of a peptidoglycan so as to prevent peritonitis in the patient; and providing the peritoneal dialysis solution to the patient.
In an embodiment, the peritoneal dialysis solution includes an icoc»extrin-based solution.
In an embodiment, the peritoneal dialysis includes an automated peritoneal dialysis, a continuous ambulatory peritoneal dialysis and the like.
In an embodiment, the patient is monitored for peritonitis during peritoneal dialysis. For example, a dialysis effluent can be collected from the patient to determine an IL-6 response that correlates to an incidence of peritonitis.
In an embodiment, the reagent is used to determine if the amount of the peptidoglycan exceeds about 10 ng/mL in the peritoneal dialysis solution prior to use during peritoneal dialysis.
In yet another embodiment, the present invention provides a method of testing a peritoneal dialysis solution for an amount of a peptidoglycan that exceeds a level sufficient to cause peritonitis. The method includes adding a reagent to the peritoneal dialysis solution wherein the reagent is capable of reacting with the peptidoglycan to initiate a serine protease cascade; and determining the amount of the peptidoglycan.
For example, the icodextrin-based solution can be tested to determine if the amount of peptidoglycan exceeds about 10 ng/mL.
In still yet another embodiment, the present invention provides an icodextrin composition that includes a reagent capable of reacting with a peptidoglycan.
.
In an embodiment, a level of peptidoglycan can be established above which the product would produce sterile peritonitis.
In an embodiment, use of affinity columns with resins that bind peptidoglycan can be used to minimize the contamination of peptidoglycan in glucose polymers.
An advantage of the present invention is to provide improved peritoneal dialysis solutions.
Another advantage of the present invention is to provide improved methods for manufacturing and using peritoneal dialysis solutions that employ a detection protocol to determine the presence of peptidoglycan in the peritoneal dialysis solution.
Yet another advantage of the present invention is to provide improved testing procedures that can be employed to prevent peritonitis in patients that receive peritoneal dialysis therapy.
Yet still another advantage of the present invention is to provide an improved icodextrin composition that utilizes a detection procedure in the manufacture thereof to determine the presence of peptidoglycan.
Additional features and advantages of the present invention are described in, and will be apparent from, the following Detailed Description of the Invention and the figures.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 illustrates a correlation between IL-6 response in a PBMC assay and peptidoglycan concentration in icodextrin. IL-6 response was measured in freshly isolated monocytes from healthy volunteers. Each symbol and line represent duta from a single donor.
Figure 2 illustrates an effect of peptidoglycan on the infiltration of neutrophils in the peritoneal fluid of rats. Peritoneal fluid was collected six hours after single injection (35 mL/kg) of icodextrin containing peptidoglycan.
Figure 3 illustrates an effect of peptidoglycan on TNF-a in the peritoneal fluid of rats.
Figure 4 illustrates an effect of peptidoglycan on IL-6 in the peritoneal fluid of rats.
Figure 5 illustrates frequency (%) of aseptic peritonitis reported with use of icodextrin.
DETAILED DESCRIPTION OF THE INVENTION
The present invention generally relates to the detection of gram positive organisms and fragments thereof. In particular, the present invention relates to methods and compositions that employ the detection of peptidoglycarl in peritoneal dialysis solutions. The inventors have surprisingly discovered a novel cause of aseptic peritonitis--aseptic peritonitis associated with gram positive microbial contamination of a dialysis solution. Peptidoglycan is a major component of a gram positive bacterial cell wall and thus can serve as a marker for gram positive bacteria. Ln this regard, testing for peptidoglycans can be utilized to effectively prevent peritonitis in patients that use the peritoneal dialysis solutions, such as peritoneal dialysis solutions that contain a glucose polymer including an icodextrin and the like.
Aseptic peritonitis associated with icodextrin-based peritoneal dialysis solutions is believed to be the largest adverse event reported for a peritoneal dialysis solution due to a contaminant of microbial origin. Based on the experimental investigations as described in detail below, this suggests that peptidoglycan in the icodextrin-based peritoneal dialysis solution was the causative agent of aseptic peritonitis. Further, pharmacovigilence data as detailed below supports the effectiveness of the corrective action and manufacturing screening procedure to prevent the occurrence of peritonitis. These findings illustrate that while endotoxin is deservedly one of the more worrisome bacterial product that can cause adverse effects to patients, it is not the sole one. In this regard, non-endotoxin pyrogens, such as peptidoglycans, that have not been previously identified, are capable of producing clinically significant inflammation. Thus, this demonstrates that parenteral pharmaceutical products that pass the compendia) tests and so meet Pharmacopoeia standards may still require a further level of testing to effectively determine the efficacy and safe use of such products to better ensure quality of life issues associated with use of same.
In the present invention, non-LPS pyrogen contamination was recognized as a problem because peritoneal dialysis exchanges permitted the direct observation of peptidoglycan-induced inflammation in situ. Peptidoglycan is a heteropolyrner formed from (3 (1-4) linked N-acetylmuramic acid and N-acetyl-D-glucosamine residues crosslinked by peptide bridges. See, for example, Royce CL, Pardy RL:
Endotoxin-like properties of an extract from a symbiotic, eukaryotic cholerella-like green algae, J
Endotoxira Res 1996;3:437-44. The glycan backbone is chemically homogenous, whereas the peptides cross-linking the sugars vary. Peptidoglycan occupies approximately 40% by weight of gram positive cell wall, but about 1-10% of the total weight of the gram negative cell walls. Royce CL, Pardy RL: Endotoxin-like properties of an extract from a symbiotic, eukaryotic cholerella-like green algae, J
Endotoxin Res 1996;3:437-44. Peptidoglycan and another cell wall constituent, lipoteichoic acid, include virtually all of the major inflammatory inducing components of gram-positive cellular walls. See, for example, Sriskandan S, Cohen J: Gram-positive sepsis, In: Opal SM, Cross AS, eds. Bacterial Sepsis and Septic Shock, Philadelphia: W. B. Saunders Company, 1999:397-412.
Like endotoxins, peptidoglycans can induce cytokine production in a wide variety of cells and have long been recognized to have immunomodulatory actions.
See, for example, Garner RE, Hudson JA: Intravenous injection of candida-derived mannan results in elevated tumor necrosis factor alpha levels in serum, Infect Inzmun 1996;64:4561-6; and Schwab J: Phlogistic properties of peptidoglycan-polysaccharide polymers from cell walls of pathogenic and normal flora bacteria which colonize humans, Infect Imznun 1993;61:4535-9. However, peptidoglycans are several orders of magnitude less potent than endotoxins as provocateurs of these biological effects. See, for example, Henderson B, Poole S, Wilson M: Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis, Microbiol Rev 1996;60:316-41; and Nakagawa Y, Maeda H, Murai T: Evaluation of the in vitro pyrogen test system based on proinflammatory cytokine release from human monocytes: Comparison with a human whole blood culture test system and with the rabbit pyrogen test, Clirz Diag Lab Imznuzzol 2002;9:588-97. For example, the minimum pyrogenic dose of peptidoglycans in rabbits is 7.3 ~,g/kg, while that of endotoxins is 0.0027 ~,g/kg. See, for example, Henderson B, Poole S, Wilson M:
Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis, Microbiol Rev 1996;60:316-41.
In addition to the absence of pyrogenic containing substances, safety of parenteral products are generally defined by Pharmacopoeia tests to determine their sterility. Bacterial cultures are generally performed at neutral pH using an incubation temperature between 20-35°C. These are suboptimal conditions for the growth of thermophilic, acidophilic microorganisms such as Alic~clobacillus acidocaldarius that require an acid medium and elevated temperature for growth. Therefore, routinely employed "sterility definitions" and the supporting assays may fail to detect microorganisms that do not grow under conventional conditions. In an embodiment of the present application, acid hydrolysis at an elevated temperature is used for hydrolysis of starch to produce icodextrin. These manufacturing conditions are suitable for the growth of Alicycclobacillus acidocadarius, but discordant with those used to determine sterility based on bioburden.
As referenced above, a detailed description of the investigative findings are provided below in accordance with an embodiment of the present invention by way of example and without limitation:
CHEMICAL AND PHYSICAL INVESTIGATIONS
The majority of glucose molecules in icodextrin are linearly linked with a (1-4) glucosidic bonds (>90%), while a small fraction (<10%) are linked by a (1-6) bonds.
Molecular weight distribution of icodextrin was performed by gel permeation chromatography. The distribution of a(1-3 6 ) and a(l~ 4) glucosidic links in icodextrin was assessed by nuclear magnetic resonance spectroscopy. Volatile and semi-volatile organic impurities were examined by high performance liquid chromatography and mass spectroscopy.
DIALYSATE EFFLUENT ANALYSIS
Dialysate effluent samples from patients were analyzed for icodextrin metabolites, triglycerides, total protein and selective pyrogenic cytokines (IL-6, TL-1,Q
and TNF-a). Icodextrin metabolites were assayed using high performance anion exchange chromatography with pulsed amperometric detection. See, for example, Burke RA, Hvizd MG, Shockley TR: Direct determination of polyglucose metabolites in plasma using anion-exchange chromatography with pulsed amperometric detection, J Claromatogr B 1997;693:353-7. Triglyceride and protein analysis were performed with Boehringer Mannheim/Hitachi 911 Chemistry analyzer. Cytokine measurements were made using ELISA kits (R&D Systems, Minneapolis, MN).
MEASUREMENT OF PYROGENS
Endotoxin concentration in icodextrin solution was determined by a fixed point chromogenic LAL test. See, for example, Weary M, Dubczak J, Wiggins J, et al:
Validating an LAL chromogenic substrate pyrogen test for large volume parenterals, In: Watson SW, Levin J, Novitsky TJ, eds, Detection of bacterial endotoxin with limulus amebocyte lysate test. New York: Alan R. Liss, 1987:307-22. Rabbit pyrogen test was performed in accordance with the guidelines provided in the European Pharmacopeia. European Pharmacopoeia, Pyrogens, 4th ed. Strasbourg, France:
Council of Europe, 2002:131-2. An ex vivo pyrogen test that measures IL-6 response in freshly isolated peripheral blood mononuclear cells (PBMC) following exposure to a test substance was used to quantitate non-endotoxin pyrogens. See, for example, Dinarello CA, O'Conner JV, LoPreste G: Human leukocyte pyrogen test for detection of pyrogenic material in growth hormone produced by recombinant Escherichia coli, J
Clih Microbiol 1984;20:323-9; and Poole S, Thorpe R, Meager A, et al:
Detection of pyrogen by cytokine release, Lancet 1988;1 (8577):130.
MEASUREMENT OF PEPTIDOGLYCANS
Peptidoglycan (PG) quantitation was performed with the silkworm larvae plasma (SLP) test (Wako Pure Chemical Industries, Ltd., Osaka, Japan). See, for example, Tsuchiya M, Asahi N, Suzouki F: Detection of peptidoglycan and B-glucan with silkworm larvae plasma test, FEMS InznZUrzol Medical Micrbiol 1996;15:129-34;
and U.S. Patent No. 4,970,152. SLP contains all the factors of the prophenol oxidase (PPO) cascade, a self defense mechanism of insects. The PPO cascade is initiated by peptidoglycan, in which PPO is ultimately activated to phenol oxidase. The phenol oxidase activity is colorimetrically detected with 3,4-dihydroxyphenylalanine as a substrate. The limit of detection of peptidoglycan in icodextrin solution was found to be 7.4 nglmL. The SLP test does not detect endotoxins.
As fully disclosed in U.S. Patent No. 4,970,152, for example, the detection of peptidoglycan (or (3-G) can be carried out as follows. A sample containing the peptidoglycan is well mixed with a reagent that includes a fraction which specifically reacts with peptidoglycan ("PG") to prepare a reaction solution. After a certain period of time, an enzymatic activity, e.g., activity of BAEEase, PPAE, PO, etc., in the reaction solution can be measured by a conventional method and compared with calibration curves previously obtained by using PG standard solutions with known concentrations to determine the amount of PG.
Alternatively, it is possible to apply a phenomenon that a time required for the activation of PO depends on the concentration of PG in the sample. That is, after mixing the PG reagent with a sample in the presence of the substrate of PO, a time required for reaching a certain value of the amount of reaction product generated by PO is measured.
By way of example and not limitation, an experimental procedure that utilizes the SLP test can be conducted in accordance with an embodiment of the present invention as follows.
Peptidoglycan (PG) and (1,3)--D-glucan (BG) are components of the cell walls of gram positive bacteria and fungi, respectively. PG and BG are measured with the Silkworm Larvae Plasma (SLP) test. The SLP test contains all the factors of the pro-phenol oxidase (PPO) cascade, an important self defense mechanism of insects.
The PPO cascade is initiated by peptidoglycan, in which PPO converts 3,4-dihydroxyphenylalanine (DOPA) to melanin. The resulting formation of melanin is colorimetrically detected at 650 nm using a standard plate reader. The raw material icodextrin is tested undiluted and has a limit of detection (LOD) of 0.74 ng/ml (the lowest detectable standard point). The finished product, such as EXTRANEAL, is tested after diluting tenfold in order to mitigate the matrix inhibition caused by the presence of electrolytes. The sample dilution step results in a LOD of 7.4 ng/ml after correcting for the 1:10 dilution.
ANIMAL STUDIES
No Observed Effect Level (NOEL) for peptidoglycan in icodextrin was determined in a rat model. A total of 45 male Sprague-Dawley rats (Harlan Inc;
Indianapolis, IN, USA), weighing 255-280 g were divided into 9 equal groups.
Each group received a single intraperitoneal injection of icodextrin spiked with 0, l, 5, 10, 50, 100, 500, 1000 or 5000 ng/mL peptidoglycan at a dose of 35 mLlkg.
Peptidoglycan derived from Staphylococcus aureus (Toxin Technology Inc., Sarasota, FL, USA) was used in these experiments. Six hours post injection, the rats were sacrificed, and the fluid in the peritoneal cavity was quantitatively collected by determining the weight and volume. Peritoneal fluid was analyzed for nucleated cell counts and differential counts, total protein, 'and TL-6 and TNF-a concentrations.
STATISTICAL ANALYSIS
Post market surveillance data on several hundred batches of icodextrin manufactured between July 2000 and September 2002 were analyzed to determine an association between peptidoglycan level and the incidence of aseptic peritonitis. To accumulate sufficient complaint frequencies to effectively display complaints per million (CPM), data were classified into peptidoglycan level in a log scale, namely, ~.4, >7.4-15, >15-30, >30-60, and _60 ng/mL. For each of peptidoglycan concentration range, the total complaints and the total units sold were calculated. The CPM units sold were computed as the total complaints divided by the total units sold multiplied by one million. Negative binomial regression was used to assess the association between CPM and peptidoglycan level. The statistical analysis was performed using the SAS procedure GENMOD (SAS Institute, Cary, NC, USA).
CLINICAL CASES
According to reports received through the BAXTER HEALTHCARE
CORPORATION's global pharmacovigilance system in 2000, the frequency [(number of complaints = number of patients treated) x 100] of aseptic peritonitis was 0.095%.
There was a steady increase in reported cases in 2001 to a peak frequency of 1.04% in March 2002. The patients were rarely febrile or toxic in appearance; abdominal pain was modest to absent; the dialysate was cloudy and cellular with dialysate cell counts varying from 300 to 3500/mm3 (variable percentages of neutrophils, lymphocytes, and macrophages without eosinophils). Unlike bacterial peritonitis, there was no change in ultrafiltration or peritoneal permeability for small solutes. Blood and dialysate cultures were invariably negative. Antibiotics were variably instituted by the local physicians.
All clinical signs resolved upon stopping icodextrin. In some cases, icodextrin was restarted, and aseptic peritonitis recurred. BAXTER HEALTHCARE
CORPORATION initiated a voluntary worldwide recall of several hundred batches of icodextrin in May 2002.
Extensive chemical and physical investigations of recalled icodextrin batches were performed. These analyses did not reveal any differences in molecular weight distribution of icodextrin, percent branching of glucosidic bonds, or trace volatile and semi-volatile organic impurities between the batches associated with aseptic peritonitis and those not associated with adverse clinical events. All solution components of complaint batches of icodextrin-containing dialysate were within the product specifications and met current Pharmacopoeia standards.
DIALYSATE EFFLUENT ANALYSIS
A marked elevation in IL-6 concentration was observed in the dialysate effluent from a patient with aseptic peritonitis compared to control effluent (>5000 versus 59 pg/mL, respectively). An increase in protein concentration was noted with the complaint sample compared to the control (236 mg/dL versus 125 mg/dL, respectively). There was no difference in icodextrin and its metabolites (glucose polymers with degree of polymerization from 2 to 7) between the complaint and control samples. These results indicated that neither icodextrin nor its metabolites were the likely cause of aseptic peritonitis.
PYROGEN ANALYSIS OF ICODEXTRIN
Endotoxin levels in all the icodextrin samples associated with aseptic peritonitis were found to be within the product limit (c 0.25 EU/mL) as determined by i the LAL test. In rabbit pyrogen tests, there was no increase in temperature with either complaint or non-complaint icodextrin batches. However, an increase in IL-6 response in the in vitro PBMC assay was observed with both complaint icodextrin-containing dialysate batches and the icodextrin raw material used to manufacture the complaint batches of peritoneal dialysate as illustrated in Table 1 below:
Tablel : IL-6 response of complaint and non-complaint batches of icodextrin in the PBMC assay. In this assay, an IL-6 response of greater than 500 pg/mL is considered a positive pyrogenic response.
Test Sample Donor 023 Donor 022 Donor 011 pg/mL pg/mL pg/mL
Control Mediums 45 24 50 Positive Control 12,000 10,000 10,000 Negative Control 130 92 150 Icodextrin (non-complaint)330 350 110 Icodextrin (complaint) 5,100 7,000 970 Icodextrin (complaint) 4,200 4,200 700 Icodextrin raw material 9,300 780 1,600 (complaint) Icodextrin raw material 91 100 130 (non-complaint) aEagle minimum essential medium with supplemental components, bBaxter experimental product, °Glucose containing standard peritoneal dialysis solution The IL-6 provoking substance in the complaint samples was unaffected in the presence of polymyxin B, thus suggesting that it was not LPS. See, for example, Pool EJ, Johaar G, James S, et al: Differentiation between endotoxin and non-endotoxin pyrogens in human albumin solutions using an ex vivo whole blood culture assay, J
Immunoassay 1999;20:79-89. In a filtration experiment using a 30 kD molecular weight cut-off filter, the contaminant producing the inflammatory response in the PBMC assay was found in the retentate, suggesting the molecular weight of the substance was >30 kD, i.e. larger than icodextrin. The negative assays for LPS, but positive PBMC IL-6 response indicated that the likely cause of aseptic peritonitis was a non-endotoxin, pyrogen contaminant in icodextrin raw material used to manufacture the final peritoneal dialysis solution.
PEPTIDOGLYCAN AND MICROBIOLOGICAL ANALYSIS
Analysis of several hundred recalled batches of icodextrin indicated that 41 of the batches were contaminated with peptidoglycan that was detected by the SLP
assay. Peptidoglycan concentrations ranged from the detection limit of 7.4 ng/mL to 303 ng/mL. Because the manufacture of icodextrin from maltodextrin requires heat and acidification, a microbiological investigation for the presence of fastidious organisms was undertaleen. Early steps of icodextrin were found to be contaminated with a thermophilic, acidiophilic, gram positive organism, Alicyclobacillus acidocaldarius. Alicyclobacillus was the source of the contaminating peptidoglycan.
Heat and sterile filtration procedures applied to the near final product eliminated the bacteria, but not the peptidogycan contaminants. A positive correlation was found between peptidoglycan levels in icodextrin and the IL-6 response observed in the PBMC assay (See, Fig.l). Substantial variability in the IL-6 response was seen between donors suggesting a range of sensitivities to peptidoglycan.
ANIMAL STUDIES
The effects of intraperitoneal administration of peptidoglycan in rats was investigated in order to establish a NOEL. This can be used to establish a regulatory specification for icodextrin manufacturing. Total protein, white blood cells and neutrophils were elevated in the peritoneal fluid of icodextrin +
peptidoglycan-treated rats compared to control rats that received icodextrin without peptidoglycan.
Infiltration of neutrophils in peritoneal fluid showed a dose dependent increase with a NOEL at 100 ng/mL (See, Fig.2). Both inflammatory cytokines showed dose dependent increases with NOEL values at 10 ng/mL for TNF-a (See, Fig.3) and ng/mL for IL-6 (See, Fig.4). The lowest NOEL for peptidoglycan was for TNF-a response which was 10 ng/mL.
CORRELATION BETWEEN PEPTIDOGLYCAN AND ASEPTIC PERITONITIS
A positive correlation was found between peptidoglycan concentration in icodextrin and CPM as illustrated in Table 2 below:
Table 2: Correlation between Complaints Per Million (CPM) units sold and peptidoglycan concentration in icodextrin solution Peptidoglycan (ng/mL)Total units Total complaintsCPM per units sold solda <'7.4 2906643 53 18.2 > 7.4 - 15 835539 10 12.0 > 15 - 30 349503 10 28.6 > 30 - 60 231330 8 ' 34.6 >_60 415099 105 253.0 aComplaints Per Million (CPM) units sold was computed as the total complaints divided by the total units sold multiplied by one million.
The baseline CPM was 18.2, when peptidoglycan levels were below the detection limit of 7.4 ng/mL. In contrast, the CPM was 252.9, when peptidoglycan levels were equal to or greater than 60 ng/mL. The association between CPM and peptidoglycan was highly significant (p<0.0001).
INCIDENCE OF ASEPTIC PERITONITIS FOLLOWING CORRECTIVE ACTION
In May 2002, BAXTER HEALTHCARE CORPORATION recalled all batches of icodextrin contaminated with peptidoglycan at a concentration >10 ng/mL, as well as all lots that were not assayed for peptidoglycan at the time of the recall.
In addition, an internal regulatory specification for peptidoglycan below the detection limit of the assay (<7.4 ng/mL) was implemented for product release. Routine, serial monitoring for peptidoglycan and thermophilic bacteria was implemented. The peptidoglycan concentrations in all the recent batches manufactured have been below the detection limit of the SLP test and are. devoid of an IL-6 eliciting agent by the PBMC
assay.
Fig. 5 shows the incidence rate of aseptic peritonitis by month beginning September 2001 to January 2003. The frequency of complaints has decreased from a peak value of 1.04% in March 2002 to 0.013% in January 2003 following the implementation of corrective actions. The number of patients using a commercially available peritoneal dialysis ' solution known as EXTRANEAL from BAXTER
HEALTHCARE CORPORATION during this period remained at approximately 7,000. These results suggest that corrective actions have been effective in preventing excess complaints of aseptic peritonitis due to peptidoglycan contamination in icodextrin-containing dialysis solution.
As previously discussed, the present invention relates to methods and compositions that employ the detection of peptidoglycan in peritoneal dialysis solutions. This allows testing for bacterial fragments as peptidoglycans are the major cell wall component of gram positive organisms. In this regard, peptidoglycan detection can be effectively utilized to prevent peritonitis in patients that use the peritoneal dialysis solutions, such as peritoneal dialysis solutions that contain a glucose polymer including icodextrin and the like.
It should be appreciated that compositions, peritoneal dialysis solutions and methods of manufacturing and using same can be provided in any suitable manner in accordance with an embodiment of the present invention. In an embodiment, the present invention provides bioburden testing, such as bioburden testing for acidophilic thermophilic organisms according to standard procedures as described in various Pharmacopoeias. This type of testing can be utilized as an added level of testing in addition to the testing for bacterial fragments by detection of peptidoglycans as previously discussed.
In an embodiment, the present invention provides methods for manufacturing a peritoneal dialysis solution. The method can include any suitable number and type of processing stages. For example, the process includes providing a glucose polymer;
adding a reagent to the glucose polymer wherein the reagent is capable of reacting with a peptidoglycan; determining an amount of the peptidoglycan; and using the glucose polymer to make the peritoneal dialysis solution if it is determined that a sufficiently low level of the peptidoglycan is present in the glucose polymer.
If the amount of peptidoglycan or the like exceeds this level, such as about 10 ng/mL
or less, the glucose polymer can be further processed to remove the peptidoglycan or the like in order to achieve a sufficiently low level of same. The glucose polymer can be further processed in any suitable manner. In an embodiment, the glucose polymer can be processed with any suitable number and type of separation devices, such as an affinity device and/or the like.
In an embodiment, the present invention provides compositions, such as glucose polymer compositions that can be used to prepare peritoneal dialysis solutions.
A variety of different and type of compositions and solutions containing same can be utilized. For example, the type of compositions and solutions can same can be found in U.S. Patent No. 4,761,237, entitled "PERITONEAL DIALYSIS SOLUTION
CONTAINING CARBOHYDRATE POLYMERS; LT.S. Patent No. 4,886,789, entitled "PERITONEAL DIALYSIS AND COMPOSITIONS FOR USE THEREIN"; U.S.
Patent No. 6,077,836, entitled "PERITONEAL DIALYSIS AND COMPOSITIONS
FOR USE THEREIN"; AND U.S. Patent No. 6,248,726 Bl, entitled "METHOD OF
PERITONEAL DIALYSIS USING GLUCOSE POLYMER SOLUTIONS, the disclosures of which in their entirety are incorporated herein by reference.
Additional examples of compositions and solutions containing same can be can be found in U.S.
Patent Application No.lO/327,264, entitled BIOCOMPATIBLE DIALYSIS FLUIDS
CONTAINING ICODEXTR1NS, filed on December 20, 2002; and U.S. Patent Application No. 09/206,063, entitled PERITONEAL DIALYSIS SOLUTION
CONTAINING MODIFIED ICODEXTRINS, filed on December 4, 1998, the disclosures of which in their entirety are incorporated herein by reference.
In an embodiment, the peritoneal dialysis solutions can include EXTRANEAL by BAXTER
HEALTHCARE CORPORATION or suitable modifications thereof.
In an embodiment, the present invention includes methods of providing peritoneal dialysis, such as continuous ambulatory peritoneal dialysis and automated peritoneal dialysis. In continuous ambulatory peritoneal dialysis, the patient performs several drain, fill, and dwell cycles during the day, for example, about four times per day. Each treatment cycle, which includes a drain, fill and dwell, takes about four hours.
Automated peritoneal dialysis is similar to continuous ambulatory peritoneal dialysis in that the dialysis treatment includes a drain, fill, and dwell cycle. However, a dialysis machine automatically performs three or more cycles of peritoneal dialysis treatment, typically overnight while the patient sleeps.
With automated peritoneal dialysis, an automated dialysis machine fluidly connects to an implanted catheter or the like. The automated dialysis machine also fluidly connects to a source or bag of fresh dialysis solution and to a fluid drain. The dialysis machine pumps spent dialysis solution from the peritoneal cavity, through the catheter, to the drain. The dialysis machine then pumps fresh dialysis solution from the source, through the catheter, and into the patient's peritoneal cavity.
The automated machine allows the dialysis solution to dwell within the cavity so that the transfer of waste, toxins and excess water from the patient's bloodstream to the dialysis solution can take place. A computer controls the automated dialysis machine so that the dialysis treatment occurs automatically when the patient is connected to the dialysis machine, for example, when the patient sleeps. In this regard, the dialysis system automatically and sequentially pumps fluid into the peritoneal cavity, allows for dwell, pumps fluid out of the peritoneal cavity, and repeats the procedure.
Several drain, fill, and dwell cycles will occur during the treatment. Also, a final volume "last fill" is typically used at the end of the automated dialysis treatment, which remains in the peritoneal cavity of the patient when the patient disconnects from the dialysis machine for the day. Automated peritoneal dialysis frees the patient from having to manually perform the drain, dwell, and fill steps during the day. In an embodiment, automated peritoneal dialysis can be performed by utilizing an admix device, such as ADMIX HOMECHOICE by BAXTER HEALTHCARE
CORPORATION or suitable modifications thereof.
In an embodiment, the present invention provides a test to determine if a peritoneal dialysis solution, such as an icodextrin-based solution, includes peptidoglycan that exceeds a level sufficient to cause peritonitis in the patient that uses same. The present invention provides a detection protocol that utilizes a reagent, such a reagent derived from a silkworm larvae plasma, for such purpose. It should be appreciated that the detection procedure can be carried out at any suitable stage prior to use of the peritoneal dialysis solution.
For example, the reagent can be added to a glucose polymer composition, such as an icodextrin composition, in raw material form to determine the presence of peptidoglycan. If the level of peptidoglycan is at a sufficiently low level, the composition can then be utilized to prepare the peritoneal dialysis solution.
In another embodiment, the reagent can be added to the peritoneal dialysis solution, such as after the sterilization process in finished product form. For example, the reagent can be added to the peritoneal dialysis solution that is contained within any suitable solution bag, such as a single-chambered solution bag or a mufti-chamber solution bag.
An example of a mufti-chamber solution bag or container is provided in U.S.
Patent No.
5,431,496, the disclosure of which in its entirety is incorporated herein by reference.
As described herein, all patent applications and publications including patent publications are incorporated herein by reference in their entirety.
It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art.
Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.
As described herein, all patent applications and publications including patent publications are incorporated herein by reference in their entirety.
It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art.
Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.
Claims (31)
1. A method for manufacturing a peritoneal dialysis solution, the method comprising the steps of:
providing a glucose polymer;
adding a reagent to the glucose polymer wherein the reagent is capable of reacting with a peptidoglycan;
determining an amount of the peptidoglycan; and using the glucose polymer to make the peritoneal dialysis solution if it is determined that a sufficiently low level of the peptidoglycan is present.
providing a glucose polymer;
adding a reagent to the glucose polymer wherein the reagent is capable of reacting with a peptidoglycan;
determining an amount of the peptidoglycan; and using the glucose polymer to make the peritoneal dialysis solution if it is determined that a sufficiently low level of the peptidoglycan is present.
2. The method of Claim 1, wherein the reaction initiates a serine protease cascade.
3. The method of Claim 2, wherein the serine protease cascade includes a prophenol oxidase cascade.
4. The method of Claim 1, wherein the reagent is derived from a silkworm larvae plasma.
5. The method of Claim 1, wherein the amount of peptidoglycan is further determined by a colorimetric measurement in response to the reaction between the peptidoglycan and the reagent.
6. The method of Claim 1, wherein the sufficiently low level of the peptidoglycan is about 10 ng/mL or less.
7. The method of Claim 1, wherein the glucose polymer-based solution includes an icodextrin.
8. The method of Claim 7, wherein the reagent is added to the glucose polymer-based solution.
9. The method of Claim 1, further comprising the step of removing the peptidoglycan to provide the sufficiently low level of same if it is determined that the sufficiently low level of the peptidoglycan is not present.
10. The method of Claim 1, wherein the glucose polymer includes an icodextrin.
11. A method of providing peritoneal dialysis to a patient, the method comprising the steps of:
preparing a peritoneal dialysis solution utilizing a reagent to ensure that the peritoneal dialysis solution has a sufficiently low level of a peptidoglycan so as to prevent peritonitis in the patient; and providing the peritoneal dialysis solution to the patient.
preparing a peritoneal dialysis solution utilizing a reagent to ensure that the peritoneal dialysis solution has a sufficiently low level of a peptidoglycan so as to prevent peritonitis in the patient; and providing the peritoneal dialysis solution to the patient.
12. The method of Claim 11, wherein the sufficiently low level of the peptidoglycan includes about 10 ng/mL or less.
13. The method of Claim 11, wherein the peritoneal dialysis solution includes a glucose polymer-based solution.
14. The method of Claim 13, wherein the glucose polymer-based solution includes an icodextrin.
15. The method of Claim 11, wherein the peritoneal dialysis is selected from the group consisting of an automated peritoneal dialysis and a continuous ambulatory peritoneal dialysis.
16. The method of Claim 11, wherein the patient is monitored for peritonitis during peritoneal dialysis.
17. The method of Claim 16, wherein a dialysis effluent is collected from the patient to determine an IL-6 response that correlates to an incidence of peritonitis.
18. The method of Claim 11, wherein the reagent is used to determine if the amount of the peptidoglycan exceeds about 10 ng/mL in the peritoneal dialysis solution prior to use during peritoneal dialysis.
19. The method of Claim 18, wherein the reagent is derived from a silkworm larvae plasma.
20. A method of testing a peritoneal dialysis solution for a presence of a gram positive organism that exceeds a level sufficient to cause peritonitis, the method comprising the steps of:
adding a reagent to the peritoneal dialysis solution wherein the reagent is capable of reacting with the peptidoglycan to initiate a serine protease cascade; and determining the amount of the peptidoglycan.
adding a reagent to the peritoneal dialysis solution wherein the reagent is capable of reacting with the peptidoglycan to initiate a serine protease cascade; and determining the amount of the peptidoglycan.
21. The method of Claim 20, wherein the serine protease cascade includes a prophenol oxidase cascade.
22. The method of Claim 21, wherein the reagent is derived from a silkworm larvae plasma.
23. The method of Claim 20, wherein the peritoneal dialysis solution includes a glucose polymer-based solution.
24. The method of Claim 23, wherein the glucose polymer-based solution includes an icodextrin.
25. The method of Claim 23, wherein the reagent is added to a glucose polymer in a raw material form that is used to make the glucose polymer-based solution.
26. The method of Claim 23, wherein the glucose polymer-based solution is tested for the amount of peptidoglycan that exceeds about 10 ng/mL.
27. A glucose polymer composition comprising a reagent that is capable of reacting with a peptidoglycan.
28. The glucose polymer composition of Claim 27, wherein the reagent is capable of reacting with the peptidoglycan to initiate a serine protease cascade.
29. The glucose polymer composition of Claim 28, wherein the serine protease cascade includes a prophenol oxidase cascade.
30. The glucose polymer composition of Claim 27, wherein the reagent is derived from a silkworm larvae plasma.
31. The glucose polymer composition of Claim 27, wherein the glucose polymer composition is an icodextrin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/789,320 US7118857B2 (en) | 2004-02-27 | 2004-02-27 | Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions |
| US10/789,320 | 2004-02-27 | ||
| PCT/US2005/005187 WO2005093087A1 (en) | 2004-02-27 | 2005-02-18 | Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2555209A1 true CA2555209A1 (en) | 2005-10-06 |
Family
ID=34887248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002555209A Abandoned CA2555209A1 (en) | 2004-02-27 | 2005-02-18 | Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US7118857B2 (en) |
| EP (1) | EP1720999B1 (en) |
| JP (2) | JP5334412B2 (en) |
| KR (1) | KR100940173B1 (en) |
| CN (2) | CN101879181A (en) |
| AR (2) | AR047900A1 (en) |
| AT (1) | ATE421997T1 (en) |
| AU (1) | AU2005226756B2 (en) |
| BR (1) | BRPI0508219A (en) |
| CA (1) | CA2555209A1 (en) |
| DE (1) | DE602005012574D1 (en) |
| DK (1) | DK1720999T3 (en) |
| ES (1) | ES2321631T3 (en) |
| PL (1) | PL1720999T3 (en) |
| SG (2) | SG145769A1 (en) |
| TW (1) | TWI344368B (en) |
| WO (1) | WO2005093087A1 (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8450079B2 (en) | 2003-10-31 | 2013-05-28 | Immunetics, Inc. | Method for detecting bacteria |
| US7118857B2 (en) | 2004-02-27 | 2006-10-10 | Baxter International Inc. | Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions |
| US8202248B2 (en) | 2004-08-18 | 2012-06-19 | Sequana Medical Ag | Dialysis implant and methods of use |
| US20090239238A1 (en) * | 2008-03-20 | 2009-09-24 | Baxter International Inc. | Methods for measuring pro-inflammatory substance levels in dialysis solutions and dialysis components |
| US20090239819A1 (en) * | 2008-03-20 | 2009-09-24 | Run Wang | Peritoneal dialysis solution test method |
| EP2273995B2 (en) | 2008-03-20 | 2023-11-15 | Baxter International Inc. | Destruction of microbial products by enzymatic digestion |
| US20090269733A1 (en) * | 2008-04-23 | 2009-10-29 | Azko, Inc. | Devices and Methods for the Rapid Analysis of Pathogens in Biological Fluids |
| US8882700B2 (en) | 2008-05-02 | 2014-11-11 | Baxter International Inc. | Smart patient transfer set for peritoneal dialysis |
| US9348975B2 (en) | 2008-05-02 | 2016-05-24 | Baxter International Inc. | Optimizing therapy outcomes for peritoneal dialysis |
| US8057679B2 (en) | 2008-07-09 | 2011-11-15 | Baxter International Inc. | Dialysis system having trending and alert generation |
| US8377012B2 (en) | 2009-01-30 | 2013-02-19 | Baxter International Inc. | Transfer sets for therapy optimization |
| US8282829B2 (en) | 2009-05-20 | 2012-10-09 | Baxter International Inc. | System and method for automated data collection of twenty-four hour ultrafiltration and other patient parameters using wired or wireless technology |
| US9020827B2 (en) | 2009-10-16 | 2015-04-28 | Baxter International Inc. | Peritoneal dialysis optimized using a patient hand-held scanning device |
| FR2955861B1 (en) | 2010-02-02 | 2013-03-22 | Roquette Freres | SOLUBLE GLUCOSE BRANCHES POLYMERS FOR PERITONEAL DIALYSIS |
| WO2012109473A2 (en) * | 2011-02-09 | 2012-08-16 | University Of Massachusetts | Detection of endotoxins |
| US9861733B2 (en) | 2012-03-23 | 2018-01-09 | Nxstage Medical Inc. | Peritoneal dialysis systems, devices, and methods |
| EP3536361B1 (en) | 2011-03-23 | 2020-10-07 | NxStage Medical Inc. | Peritoneal dialysis systems, devices, and methods |
| EP2609918A1 (en) * | 2011-12-27 | 2013-07-03 | Zytoprotec GmbH | Peritoneal dialysis fluid comprising a GSK-3 inhibitor |
| US8585635B2 (en) | 2012-02-15 | 2013-11-19 | Sequana Medical Ag | Systems and methods for treating chronic liver failure based on peritoneal dialysis |
| CN104364648B (en) * | 2012-05-29 | 2017-04-26 | 罗盖特兄弟公司 | Methods for decontaminating circuits for producing glucose polymers and hydrolysates of glucose polymers |
| JP6027684B2 (en) | 2012-09-25 | 2016-11-16 | ゼネラル・エレクトリック・カンパニイ | Disposable containers for collecting and detecting bioburden samples |
| US9227005B2 (en) * | 2013-03-14 | 2016-01-05 | Brian J LeBerthon | Method and device for treating cancer |
| US9857355B2 (en) | 2013-03-26 | 2018-01-02 | Roquette Freres | Biological assay of peptidoglycans |
| US9382591B2 (en) * | 2013-06-06 | 2016-07-05 | Pall Corporation | Compositions for detecting Alicyclobacillus microorganisms |
| CN103467608B (en) * | 2013-09-27 | 2015-08-26 | 华仁药业股份有限公司 | Icodextrin and preparation method thereof |
| RU2641960C2 (en) * | 2013-12-16 | 2018-01-23 | Дмитрий Анатольевич Складнев | Method for detecting microbial and viral contamination of solutions and biological fluids |
| MX2016009774A (en) * | 2014-02-07 | 2016-11-14 | Roquette Freres | Biological dosage of peptidoglycans. |
| WO2017176695A1 (en) * | 2016-04-04 | 2017-10-12 | Medtronic, Inc. | Peritoneal dialysate fluid generation system |
| US10769244B2 (en) | 2016-08-26 | 2020-09-08 | Sequana Medical Nv | Systems and methods for managing and analyzing data generated by an implantable device |
| GB201616718D0 (en) * | 2016-09-30 | 2016-11-16 | Microbiosensor Limited | Microbial sensing devices |
| US11559618B2 (en) | 2017-05-24 | 2023-01-24 | Sequana Medical Nv | Formulations and methods for direct sodium removal in patients having severe renal dysfunction |
| AU2018223035A1 (en) * | 2017-10-03 | 2019-04-18 | Medtronic, Inc. | Peritoneal dialysate temperature regulation system |
| CA3092575A1 (en) | 2018-02-28 | 2019-09-06 | Nxstage Medical, Inc. | Fluid preparation and treatment devices, methods, and systems |
| CN109264812A (en) * | 2018-11-13 | 2019-01-25 | 华仁药业股份有限公司 | One kind is for removing endotoxic method in glucidtemns |
| CN109400722A (en) * | 2018-11-13 | 2019-03-01 | 华仁药业股份有限公司 | A method of for removing peptide glycan in glucidtemns |
| US11280788B2 (en) * | 2019-01-31 | 2022-03-22 | Fresenius Medical Care Holdings, Inc. | Rapid diagnosis of peritonitis in peritoneal dialysis patients |
| WO2023170680A1 (en) | 2022-03-08 | 2023-09-14 | Equashield Medical Ltd | Fluid transfer station in a robotic pharmaceutical preparation system |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4761237A (en) * | 1981-07-10 | 1988-08-02 | Baxter Travenol Laboratories, Inc. | Peritoneal dialysis solution containing carbohydrate polymers |
| US6077836A (en) * | 1983-01-12 | 2000-06-20 | Ml Laboratotries, Plc | Peritoneal dialysis and compositions for use therein |
| US4886789A (en) * | 1983-01-12 | 1989-12-12 | M. L. Laboratories Plc | Peritoneal dialysis and compositions for use therein |
| DE3689863T2 (en) | 1985-06-22 | 1995-01-05 | Ml Lab Plc | Polymers used in continuous peritoneal dialysis. |
| US6248726B1 (en) * | 1985-06-22 | 2001-06-19 | M L Laboratories Plc | Method of peritoneal dialysis using glucose polymer solutions |
| EP0634656B1 (en) * | 1986-12-03 | 2000-01-12 | Wako Pure Chemical Industries, Ltd. | Processes for collecting body fluid from insects |
| DE4242926C2 (en) | 1992-12-18 | 1994-12-15 | Fresenius Ag | Dialysis solution for peritoneal dialysis |
| DK0636018T3 (en) * | 1993-01-19 | 1997-12-08 | Baxter Int | Multi-chamber container |
| FR2716199B1 (en) | 1994-02-15 | 1996-04-26 | Roquette Freres | Process for the manufacture of a starch hydrolyzate with a low polymolecularity index, a new starch hydrolyzate thus obtained and its use in peritoneal dialysis. |
| DE19748290B8 (en) | 1997-10-31 | 2009-09-03 | Fresenius Medical Care Deutschland Gmbh | Solution for peritoneal dialysis |
| US6770148B1 (en) * | 1998-12-04 | 2004-08-03 | Baxter International Inc. | Peritoneal dialysis solution containing modified icodextrins |
| JP2002037705A (en) * | 2000-07-26 | 2002-02-06 | National Agricultural Research Organization | Antibacterial agent for acid-resistant and heat-resistant bacterium |
| US20040121982A1 (en) * | 2002-12-20 | 2004-06-24 | Leo Martis | Biocompatible dialysis fluids containing icodextrins |
| US7118857B2 (en) | 2004-02-27 | 2006-10-10 | Baxter International Inc. | Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions |
-
2004
- 2004-02-27 US US10/789,320 patent/US7118857B2/en not_active Expired - Fee Related
-
2005
- 2005-02-15 TW TW094104312A patent/TWI344368B/en not_active IP Right Cessation
- 2005-02-18 WO PCT/US2005/005187 patent/WO2005093087A1/en active Application Filing
- 2005-02-18 SG SG200806252-3A patent/SG145769A1/en unknown
- 2005-02-18 KR KR1020067017109A patent/KR100940173B1/en active IP Right Grant
- 2005-02-18 BR BRPI0508219-6A patent/BRPI0508219A/en not_active IP Right Cessation
- 2005-02-18 AU AU2005226756A patent/AU2005226756B2/en active Active
- 2005-02-18 SG SG200908625-7A patent/SG158178A1/en unknown
- 2005-02-18 EP EP05713781A patent/EP1720999B1/en not_active Revoked
- 2005-02-18 PL PL05713781T patent/PL1720999T3/en unknown
- 2005-02-18 CN CN2009102463990A patent/CN101879181A/en active Pending
- 2005-02-18 DE DE602005012574T patent/DE602005012574D1/en active Active
- 2005-02-18 CA CA002555209A patent/CA2555209A1/en not_active Abandoned
- 2005-02-18 AT AT05713781T patent/ATE421997T1/en active
- 2005-02-18 ES ES05713781T patent/ES2321631T3/en active Active
- 2005-02-18 DK DK05713781T patent/DK1720999T3/en active
- 2005-02-18 JP JP2007500888A patent/JP5334412B2/en not_active Expired - Fee Related
- 2005-02-18 CN CNA200580005032XA patent/CN1918302A/en active Pending
- 2005-02-25 AR ARP050100715A patent/AR047900A1/en not_active Application Discontinuation
-
2006
- 2006-07-13 US US11/457,330 patent/US7618392B2/en active Active
-
2009
- 2009-11-13 US US12/618,442 patent/US8546097B2/en active Active
-
2011
- 2011-04-08 JP JP2011086837A patent/JP2011140519A/en active Pending
-
2013
- 2013-08-23 US US13/974,872 patent/US8859222B2/en not_active Expired - Lifetime
-
2014
- 2014-11-03 AR ARP140104124A patent/AR098287A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE421997T1 (en) | 2009-02-15 |
| KR20060126571A (en) | 2006-12-07 |
| US20060263842A1 (en) | 2006-11-23 |
| US7118857B2 (en) | 2006-10-10 |
| KR100940173B1 (en) | 2010-02-03 |
| ES2321631T3 (en) | 2009-06-09 |
| SG145769A1 (en) | 2008-09-29 |
| EP1720999B1 (en) | 2009-01-28 |
| DE602005012574D1 (en) | 2009-03-19 |
| US20130338102A1 (en) | 2013-12-19 |
| WO2005093087A1 (en) | 2005-10-06 |
| US20100056990A1 (en) | 2010-03-04 |
| AR098287A2 (en) | 2016-05-26 |
| US8546097B2 (en) | 2013-10-01 |
| BRPI0508219A (en) | 2007-07-17 |
| PL1720999T3 (en) | 2009-07-31 |
| TW200538137A (en) | 2005-12-01 |
| CN101879181A (en) | 2010-11-10 |
| US8859222B2 (en) | 2014-10-14 |
| TWI344368B (en) | 2011-07-01 |
| AU2005226756B2 (en) | 2008-08-28 |
| JP2011140519A (en) | 2011-07-21 |
| CN1918302A (en) | 2007-02-21 |
| SG158178A1 (en) | 2010-01-29 |
| US7618392B2 (en) | 2009-11-17 |
| AR047900A1 (en) | 2006-03-01 |
| EP1720999A1 (en) | 2006-11-15 |
| DK1720999T3 (en) | 2009-05-04 |
| JP2007525506A (en) | 2007-09-06 |
| JP5334412B2 (en) | 2013-11-06 |
| US20050191717A1 (en) | 2005-09-01 |
| AU2005226756A1 (en) | 2005-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005226756B2 (en) | Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions | |
| Martis et al. | Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution | |
| EP2268830B1 (en) | Peritoneal dialysis solution test method | |
| JP2015051000A (en) | Method for modulating cell surface receptors for preventing or reducing inflammation | |
| JP2011517405A5 (en) | ||
| Decker et al. | Gentamicin pharmacokinetics and pharmacodynamics during short-daily hemodialysis | |
| EP2273995B2 (en) | Destruction of microbial products by enzymatic digestion | |
| Hsieh et al. | Mild portal endotoxaemia induces subacute hepatic inflammation and pancreatic β‐cell dysfunction in rats | |
| MXPA06009699A (en) | Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions | |
| Goto et al. | The effects of sacran, a sulfated polysaccharide, on gut microbiota using chronic kidney disease model rats | |
| US20090239238A1 (en) | Methods for measuring pro-inflammatory substance levels in dialysis solutions and dialysis components | |
| Dawson | Endotoxin testing | |
| Raju et al. | Modified high-performance liquid chromatography technique for detection of vancomycin in human vitreous | |
| Baggerman et al. | Microbiological contamination of raw materials for large-volume parenterals | |
| Cooper et al. | Pyrogenicity case studies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20130218 |